

09/316624

*****STN Columbus*****

FILE 'HOME' ENTERED AT 10:03:27 ON 30 MAR 2000

=> index bioscience patents

72 FILES IN THE FILE LIST IN STNINDEX

=> s (reticulose or product (w) "r") and (rheumatoid or RA)

1 FILE CAPLUS
16 FILES SEARCHED...
24 FILES SEARCHED...
1 FILE FROSTI
37 FILES SEARCHED...
2 FILE IFIPAT
5 FILE MEDLINE
1 FILE PHIN
12 FILE PROMT
128 FILE USPATFULL
55 FILES SEARCHED...
13 FILE EUROPATFULL
66 FILES SEARCHED...

8 FILES HAVE ONE OR MORE ANSWERS, 72 FILES SEARCHED IN STNINDEX

L1 QUE (RETICULOSE OR PRODUCT (W) "R") AND (RHEUMATOID OR RA)

=> file medline caplus frosti ifipat phin promt europatfull

COST IN U.S. DOLLARS	SINCE FILE ENTRY	SESSION	TOTAL
FULL ESTIMATED COST	2.25		2.40

FILE 'MEDLINE' ENTERED AT 10:06:59 ON 30 MAR 2000
FILE 'CAPLUS' ENTERED AT 10:06:59 ON 30 MAR 2000
FILE 'FROSTI' ENTERED AT 10:06:59 ON 30 MAR 2000
FILE 'IFIPAT' ENTERED AT 10:06:59 ON 30 MAR 2000
FILE 'PHIN' ENTERED AT 10:06:59 ON 30 MAR 2000
FILE 'PROMT' ENTERED AT 10:06:59 ON 30 MAR 2000
FILE 'EUROPATFULL' ENTERED AT 10:06:59 ON 30 MAR 2000
=> s l1; dup rem l2
L2 35 L1
L3 35 DUP REM L2 (0 DUPLICATES REMOVED)

=> d 1-35 bib ab

L3 ANSWER 1 OF 35 PROMT COPYRIGHT 2000 Gale Group

AN 2000:190740 PROMT
TI Corporate Profile for Advanced Viral Research Corp.
SO Business Wire, (16 Mar 2000) pp. 1218.
PB Business Wire
DT Newsletter
LA English
WC 979

FULL TEXT IS AVAILABLE IN THE ALL FORMAT
AB Business & Medical/Health Editors
THIS IS THE FULL TEXT: COPYRIGHT 2000 Business Wire

L3 ANSWER 2 OF 35 PROMT COPYRIGHT 2000 Gale Group

AN 2000:124236 PROMT
TI Advanced Viral Research Corp. Receives Approval in Argentina for Human Clinical Studies With Antiviral & Substance R
SO Business Wire, (18 Feb 2000) pp. 125.
PB Business Wire
DT Newsletter
LA English
WC 618

FULL TEXT IS AVAILABLE IN THE ALL FORMAT
AB Health/Medical & Biotechnology Writers
THIS IS THE FULL TEXT: COPYRIGHT 2000 Business Wire

L3 ANSWER 3 OF 35 PROMT COPYRIGHT 2000 Gale Group

AN 1999:595616 PROMT
TI Oxford GlycoSciences Reports 1999 Interim Results.
SO PR Newswire, (15 Sep 1999) pp. 7794.
PB PR Newswire Association, Inc.
DT Newsletter
LA English
WC 2364
FULL TEXT IS AVAILABLE IN THE ALL FORMAT
AB - Announces Good News on Proteome Collaborations -
THIS IS THE FULL TEXT: COPYRIGHT 1999 PR Newswire Association, Inc.

L3 ANSWER 4 OF 35 PROMT COPYRIGHT 2000 Gale Group

AN 1999:497177 PROMT
TI Advanced Viral Research Corp. Announces Private Placement with Focus Investors LLC.
SO Business Wire, (5 Aug 1999) pp. 1280.
PB Business Wire
DT Newsletter
LA English
WC 305

FULL TEXT IS AVAILABLE IN THE ALL FORMAT
AB YONKERS, N.Y.--(BUSINESS WIRE)--Aug. 5, 1999--
THIS IS THE FULL TEXT: COPYRIGHT 1999 Business Wire

L3 ANSWER 5 OF 35 PROMT COPYRIGHT 2000 Gale Group

AN 1999:68088 PROMT
TI Manufacturers Alphabetic Listings.(Directory)
SO Air Conditioning, Heating & Refrigeration News, (4 Jan 1999) Vol. 206, No. 1, pp. 38(1).
ISSN: 0002-2276.
PB Business News Publishing Company
DT Newsletter
LA English
WC 84481

FULL TEXT IS AVAILABLE IN THE ALL FORMAT
AB A
THIS IS THE FULL TEXT: COPYRIGHT 1999 Business News Publishing Company

L3 ANSWER 6 OF 35 PROMT COPYRIGHT 2000 Gale Group

AN 2000:57338 PROMT
TI Manufacturers and Suppliers.(Alphabetical list of companies)
SO Lasers & Optronics, (Nov 1999) Vol. 18, No. 11, pp. S8.
ISSN: 0892-9947.
PB Cahners Publishing Company
DT Newsletter
LA English
WC 71777

FULL TEXT IS AVAILABLE IN THE ALL FORMAT
AB A
THIS IS THE FULL TEXT: COPYRIGHT 1999 Cahners Publishing Company

Subscription: \$61.00 per year. Published monthly.

L3 ANSWER 7 OF 35 PROMT COPYRIGHT 2000 Gale Group

AN 1999:757959 PROMT
TI OTHER NEWS TO NOTE.
AU Antiangiogenic, Discovering The
SO BIOWORLD Today, (18 Nov 1999) Vol. 10, No. 221.
PB American Health Consultants, Inc.
DT Newsletter
LA English
WC 1682

FULL TEXT IS AVAILABLE IN THE ALL FORMAT
AB Aastrom Biosciences Inc., of Ann Arbor, Mich., was awarded a Phase I Small Business Innovation Research grant to support the development of processes for ex vivo antigen-specific T-lymphocyte production. The \$100,000 six-month grant is from the National Institute of Allergy and Infectious Disease of the National Institutes of Health.
THIS IS THE FULL TEXT: COPYRIGHT 1999 American Health Consultants, Inc.

Subscription: \$1350.00 per year. Published daily (5 times a week). Box 740021, Atlanta, GA 30374.

L3 ANSWER 8 OF 35 EUROPATFULL COPYRIGHT 2000 WILA

GRANTED PATENT - ERTEILTES PATENT - BREVET DELIVRE

AN 582581 EUROPATFULL ED 19990516 EW 199918 FS PS
TIEN 1-SUBSTITUTED, 2-SUBSTITUTED 1H-IMIDAZO(4,5-C)QUINOLIN-4-AMINES.
TIDE 1,2-SUBSTITUIERTE 1H-IMIDAZO(4,5-C)CHINOLIN-4-AMINE.
TIFR 1-H-IMIDAZO(4,5-C)QUINOLIN-4-AMINES SUBSTITUEES EN POSITION 1 ET
SUBSTITUEES EN POSITION 2.
IN GERSTER, John, F., Post Office Box 33427, Saint Paul, MN 55133-3427, US;
CROOKS, Stephen, L., Post Office Box 33427, Saint Paul, MN 55133-3427, US;
LINDSTROM, Kyle, J., Post Office Box 33427, Saint Paul, MN 55133-3427, US
PA MINNESOTA MINING AND MANUFACTURING COMPANY, 3M Center, P.O. Box 33427, St. Paul, Minnesota 55133-3427, US
PAN 300410
AG Molyneaux, Martyn William et al, c/o Ladas & Parry, 52-54 High Holborn, London WC1V 6RR, GB
AGN 34016
OS EPB1999027 EP 0582581 B1 990506
SO Wila-EPS-1999-H18-T1
DT Patent
LA Anmeldung in Englisch; Veroeffentlichung in Englisch
DS R AT; R BE; R CH; R DE; R DK; R ES; R FR; R GB; R IT; R LI; R NL; R SE
PIT EPB1 EUROPAEISCHE PATENTSCHRIFT (Internationale Anmeldung)
PI EP 582581 B1 19990506
OD 19940216
AI EP 1992-906763 19920220
PRAI US 1991-662926 19910301
US 1991-687326 19910418
RLI WO 92-US1305 920220 INTAKZ
WO 9215582 920917 INTPNR
REP EP 145340 A EP 385630 A

L3 ANSWER 9 OF 35 EUROPATFULL COPYRIGHT 2000 WILA

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

AN 577394 EUROPATFULL UP 20000305 EW 199401 FS OS STAB
TIEN Morpholine and thiomorpholine tachykinin receptor antagonists.
TIDE Morpholin und Thiomorpholin Tachykinin Rezeptorantagonisten.
TIFR Morpholine et thiomorpholine, antagonistes du recepteur de tachykinine.
IN Dorn, Conrad P., 972 Fernwood Avenue, Plainfield, NJ 07062, US;
Hale, Jeffrey J., 233 Hazel Avenue, Westfield, NJ 07090, US;
Maccoss, Malcolm, 48 Rose Court, Freehold, NJ 07728, US;
Mills, Sander G., 13A Woodbridge Terrace, Woodbridge, NJ 07095, US;
Ladduwahetty, Tamara, 185 Buckhurst Way, Buckhurst Hill, Essex IG9 6JB, GB;
Shah, Shrenik K., 25 Denise Court, Metuchen, NJ 08840, US
PA MERCK & CO. INC., 126, East Lincoln Avenue P.O. Box 2000, Rahway New Jersey 07065-0900, US
PAN 200479
AG Quillin, Helen Kaye et al, European Patent Department, Merck & Co., Inc., Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR, GB
AGN 73841
OS ESP1994002 EP 0577394 A1 940105
SO Wila-EPZ-1994-H01-T1a
DT Patent
LA Anmeldung in Englisch; Veroeffentlichung in Englisch
DS R AT; R BE; R CH; R DE; R DK; R ES; R FR; R GB; R GR; R IE; R IT; R LI;
R LU; R NL; R PT; R SE
PIT EPA1 EUROPAEISCHE PATENTANMELDUNG
PI EP 577394 A1 19940105
OD 19940105
AI EP 1993-305086 19930629
PRAI US 1992-905976 19920629
US 1992-971448 19921104
US 1993-61914 19930519

GRANTED PATENT - ERTEILTES PATENT - BREVET DELIVRE

AN 577394 EUROPATFULL ED 19991121 EW 199945 FS PS
TIEN Morpholine and thiomorpholine tachykinin receptor antagonists.
TIDE Morpholin und Thiomorpholin Tachykinin Rezeptorantagonisten.
TIFR Morpholine et thiomorpholine, antagonistes du recepteur de tachykinine.
IN Dorn, Conrad P., 972 Fernwood Avenue, Plainfield, NJ 07062, US;
Hale, Jeffrey J., 233 Hazel Avenue, Westfield, NJ 07090, US;
Maccoss, Malcolm, 48 Rose Court, Freehold, NJ 07728, US;
Mills, Sander G., 13A Woodbridge Terrace, Woodbridge, NJ 07095, US;
Ladduwahetty, Tamara, 185 Buckhurst Way, Buckhurst Hill, Essex IG9 6JB, GB;
Shah, Shrenik K., 25 Denise Court, Metuchen, NJ 08840, US
PA Merck & Co., Inc., 126, East Lincoln Avenue P.O. Box 2000, Rahway New Jersey 07065-0900, US
PAN 200479
AG Quillin, Helen Kaye et al, European Patent Department, Merck & Co., Inc., Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR, GB
AGN 73841
OS EPB1999062 EP 0577394 B1 991110
SO Wila-EPS-1999-H45-T1
DT Patent
LA Anmeldung in Englisch; Veroeffentlichung in Englisch
DS R AT; R BE; R CH; R DE; R DK; R ES; R FR; R GB; R GR; R IE; R IT; R LI;
R LU; R NL; R PT; R SE
PIT EPB1 EUROPAEISCHE PATENTSCHRIFT
PI EP 577394 B1 19991110
OD 19940105
AI EP 1993-305086 19930629
PRAI US 1992-905976 19920629
US 1992-971448 19921104
US 1993-61914 19930519
REP EP 436334 A EP 528495 A
FR 2534915 A
ABEN Substituted heterocycles of the general structural formula: <image>
are tachykinin receptor antagonists useful in the treatment of
inflammatory diseases, pain or migraine, and asthma and calcium channel
blockers useful in the treatment of cardiovascular conditions such as
angina, hypertension or ischemia.

L3 ANSWER 10 OF 35 EUROPATFULL COPYRIGHT 2000 WILA

GRANTED PATENT - ERTEILTES PATENT - BREVET DELIVRE

AN 496617 EUROPATFULL ED 19991212 EW 199948 FS PS
TIEN Adenosine kinase inhibitors.
TIDE Adenosinkinaseinhibitoren.
TIFR Inhibiteurs de kinase d'adenosine.
IN Browne, Clinton E., 707 Marsopa Drive, Vista, California 92083, US;
Ugarkar, Bheemarao G., 3821 Azalea Glen, Escondido, CA 92025, US;
Mullane, Kevin M., 13814 Boquita Drive, De Mar, CA 92014, US;
Gruber, Harry E., 13083 Maritime Place, San Diego, CA 92130, US;
Bullough, David A., 13484 Ridley Road, San Diego, CA 92129, US;
Erion, Mark D., 13455 Mango Drive, Del Mar, CA 92104, US;
Castellino, Angelo, 3842 Mount Acadia Blvd, San Diego, CA 92111, US
PA Metabasis Therapeutics Inc., 9360 Towne Centre Drive, San Diego, CA 92121, US
PAN 2622511
AG Sexton, Jane Helen et al., J.A. KEMP & CO. 14 South Square Gray's Inn, London WC1R 5LX, GB
AGN 59301
OS EPB1999065 EP 0496617 B1 991201
SO Wila-EPS-1999-H48-T1
DT Patent
LA Anmeldung in Englisch; Veroeffentlichung in Englisch
DS R AT; R BE; R CH; R DE; R DK; R ES; R FR; R GB; R GR; R IT; R LI; R LU;
R MC; R NL; R PT; R SE
PIT EPB1 EUROPAEISCHE PATENTSCHRIFT
PI EP 496617 B1 19991201
OD 19920729
AI EP 1992-300580 19920123
PRAI US 1991-647117 19910123
US 1991-812916 19911223

L3 ANSWER 11 OF 35 EUROPATFULL COPYRIGHT 2000 WILA

GRANTED PATENT - ERTEILTES PATENT - BREVET DELIVRE

AN 481000 EUROPATFULL ED 19990530 EW 199919 FS PS
 TIEN RECEPTORS FOR FIBROBLAST GROWTH FACTORS.
 TIDE REZEPTOREN FÜR FIBROBLASTEN-WACHSTUMSFAKTOREN.
 TIFR RECEPTEURS POUR FACTEURS DE CROISSANCE DE FIBROBLASTES.
 IN WILLIAMS, Lewis, T., 53 Cragmont Avenue, San Francisco, CA 94116, US;
 JOHNSON, Daniel, E., 1241 Fourth Avenue, San Francisco, CA 94122, US;
 LEE, Pauline, E., 10081 Rio San Diego Drive, 322, San Diego, CA 91208, US
 PA THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, 300 Lakeside Drive, 22nd Floor, Oakland, California 94612-3550, US
 PAN 221072
 AG Harrison, David Christopher et al, MEWBURN ELLIS York House 23 Kingsway, London WC2B 6HP, GB
 AGN 31532
 OS EPB1999029 EP 0481000 B1 990512
 SO Wila-EPS-1999-H19-T3
 DT Patent
 LA Anmeldung in Englisch; Veroeffentlichung in Englisch
 DS R AT; R BE; R CH; R DE; R DK; R ES; R FR; R GB; R IT; R LI; R LU; R NL;
 R SE
 PIT EPB1 EUROPAEISCHE PATENTSCHRIFT (Internationale Anmeldung)
 PI EP 481000 B1 19990512
 OD 19920422
 AI EP 1990-911235 19900706
 PRAI US 1989-377003 19890706
 RLI WO 90-US3830 900706 INTAKZ
 WO 9100916 910124 INTPNR
 REP WO 90-05522 A US 4394443 A
 US 4668476 A US 4785079 A
 US 4859609 A

L3 ANSWER 12 OF 35 PROMT COPYRIGHT 2000 Gale Group

AN 1999:519135 PROMT
 TI SECTION 2: PRESS ACCESSORIES & SUPPLIES.
 SO Printing Impressions, (July 1998) Vol. 41, No. 2, pp. 88(1).
 ISSN: 0032-860X.
 PB North American Publishing Company
 DT Newsletter
 LA English
 WC 21235
 FULL TEXT IS AVAILABLE IN THE ALL FORMAT
 AB Blankets: Printing Press
 THIS IS THE FULL TEXT: COPYRIGHT 1998 North American Publishing Company

L3 ANSWER 13 OF 35 PROMT COPYRIGHT 2000 Gale Group

AN 1999:517889 PROMT
 TI Supplier Locator.
 SO Appliance Manufacturer, (Dec 1998) Vol. 46, No. 12, pp. SL-1(1).
 ISSN: 0003-679X.
 PB Business News Publishing Company
 DT Newsletter
 LA English
 WC 56911
 FULL TEXT IS AVAILABLE IN THE ALL FORMAT
 AB In this section you will find names, addresses and telephone numbers of the suppliers of the products listed in the Product Locator that follows this section. Boldface listings indicated advertisers in this issue. To obtain information about their products, circle the appropriate number on the Reader Service Card.
 THIS IS THE FULL TEXT: COPYRIGHT 1998 Business News Publishing Company

L3 ANSWER 14 OF 35 EUROPATFULL COPYRIGHT 2000 WILA

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

AN 872478 EUROPATFULL ED 19981101 EW 199843 FS OS
 TIEN Intermediates for the preparation of 1-substituted, 2-substituted

1H-imidazo(4,5-c)quinolin-4-amines.

TIDE Zwischenprodukte zur Herstellung von 1-substituierte, 2-substituierte-1H-Imidazo(4,5-c)Chinolin-4-Aminen.
 TIFR Intermediaires pour la preparation de 4-amino-1H-imidazo(4,5-c)quinolines substituees en position 1 et 2.
 IN Gerster, John F., c/o Minnesota Mining & Manu.Comp. PO Box 33427, Saint Paul, Minnesota 55133-3427, US;
 Crooks, Stephen L., c/o Minnesota Mining & Manu.Comp. PO Box 33427, Saint Paul, Minnesota 55133-3427, US;
 Lindstrom, Kyle J., c/o Minnesota Mining & Manu.Comp. PO Box 33427, Saint Paul, Minnesota 55133-3427, US
 PA MINNESOTA MINING AND MANUFACTURING COMPANY, 3M Center, P.O. Box 33427, St. Paul, Minnesota 55133-3427, US
 PAN 300410
 AG Wotherspoon, Hugh Robert, c/o Langner & Parry, 52-54 High Holborn, London WC1V 6RR, GB
 AGN 83381
 OS ESP1998073 EP 0872478 A2 981021
 SO Wila-EPZ-1998-H43-T1a
 DT Patent
 LA Anmeldung in Englisch; Veroeffentlichung in Englisch
 DS R AT; R BE; R CH; R DE; R DK; R ES; R FR; R GB; R IT; R LI; R NL; R SE
 PIT EPA2 EUROPAEISCHE PATENTANMELDUNG
 PI EP 872478 A2 19981021
 OD 19981021
 AI EP 1998-105754 19920220
 PRAI US 1991-662926 19910418
 US 1991-687326 19910418
 RLI EP 582581 DIV
 ABEN Intermediates for preparing 1-substituted, 2-substituted 1H-imidazo [4,5-c]-quinolin-4-amines of formula (I) are provided where X is selected from the group consisting of alkoxy, alkoxyalkyl, haloalkyl, hydroxyalkyl, alkylamido, amino or substituted amino wherein the substituent is alkyl, hydroxyalkyl, azido, chloro, hydroxy, 1-morpholino, 1-pyrrolidino, and alkylthio. The compounds of formula (I) function as antiviral agents, they induce biosynthesis of interferon, and they inhibit tumor formation in animal models. <image>

L3 ANSWER 15 OF 35 EUROPATFULL COPYRIGHT 2000 WILA

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

AN 859005 EUROPATFULL ED 19980830 EW 199834 FS OS
 TIEN FUCOSE DERIVATIVES, DRUGS CONTAINING THE SAME AS ACTIVE INGREDIENT, AND INTERMEDIATES FOR PRODUCING THE SAME.
 TIDE FUCOSE-DERIVATE, MEDIKAMENTE, DIE DIESE ALS WIRKSTOFF ENTHALTEN, UND ZWISCHENPRODUKTE FÜR IHRE HERSTELLUNG.
 TIFR DERIVES DE LA FUCOSE, MEDICAMENTS DONT ILS FORMENT LE PRINCIPE ACTIF, ET LEURS INTERMEDIAIRES DE FABRICATION.
 IN TSUKIDA, Takahiro, 6-9-101, Tomobuchi-cho 1-chome Miyakojima-ku, Osaka-shi Osaka 534, JP;
 KIYOI, Takao, 2-5, Hanjo 1-chome, Mino-shi Osaka 562, JP;
 ACHIHA, Toshio, 296-28, Kasuga Taishi-cho Minamikawachi-gun, Osaka 583, JP;
 MORIYAMA, Hideki, 1-3-301, Nagayoshinagaharanishi 4-chome Hirano-ku, Osaka-shi Osaka 547, JP;
 KUOKAWA, Kiriko 1-16, Shioji 2-chome, Nishinari-ku, Osaka-shi Osaka 557, JP;
 OHMOTO, Hiroshi 3-23-504, Tomobuchi-cho 1-chome, Miyakojima-ku, Osaka-shi Osaka 534, JP;
 NAKAMURA, Kenji, 13-11, Shin-imazato 4-chome Ikuno-ku Osaka-shi, Osaka 544, JP;
 KONDO, Hirosato, 6-A-210, Satsukigaokahigashi Suita-shi, Osaka 565, JP;
 WADA, Yukihisa, 6-7-405, Tomobuchi-cho 1-chome, Miyakojima-ku Osaka-shi Osaka 534, JP;
 SAITO, Tadayuki, 5-11-210, Tomobuchi-cho 1-chome Miyakojima-ku, Osaka-shi Osaka 534, JP
 PA KANEBO, LTD., 17-4 Sumida 5-chome Sumida-ku, Tokyo 131, JP
 PAN 202610
 AG Hansen, Bernd, Dr. Dipl.-Chem. et al, Hoffmann Eitle, Patent- und Rechtsanwalte, Arabellastrasse 4, 81925 Muenchen, DE

AGN 4924
 OS ESP1998056 EP 0859005 A1 980819
 SO Wila-EPZ-1998-H34-T1a
 DT Patent
 LA Anmeldung in Japanisch; Veroeffentlichung in Englisch;
 Verfahren in Englisch
 DS R AT; R BE; R CH; R DE; R DK; R ES; R FI; R FR; R GB; R GR; R IE; R
 IT;
 R LI; R LU; R MC; R NL; R PT; R SE
 PIT EPA1 EUROPAEISCHE PATENTANMELDUNG (Internationale
 Anmeldung)
 PI EP 859005 A1 19980819
 OD 19980819
 AI EP 1996-935412 19961023
 PRAI JP 1995-303476 19951026
 JP 1996-175487 19960613
 JP 1996-231482 19960812
 RLI WO 96-JP3081 961023 INTAKZ
 WO 9715585 970501 INTPNR
 ABEN A compound of the formula (I): <image> wherein X.sup1. is a group of
 one of the following formulae (1), (2) and (3): <image> R.sup1. is a
 branched long chain alkyl group, R.sup2. is .horbar.CONHR.sup3., a
 carboxyl group or a hydrogen atom, n is an integer of 0, 1 or 2, and
 R.sup3. is a lower alkyl group or a phenyl group, or a pharmaceutically
 acceptable salt thereof, which is useful as a selectin inhibitor, and
 can be used in the prophylaxis or treatment of various inflammatory
 diseases such as inflammatory dermatitis (e.g., atopic dermatitis,
 contact hypersensitivity, photodermatitis, etc.), autoimmune chronic
 diseases (e.g. rheumatoid arthritis, chronic thyroiditis,
 etc.), and ischemia-reperfusion injury.

L3 ANSWER 16 OF 35 EUROPATFULL COPYRIGHT 2000 WILA
 PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

AN 623852 EUROPATFULL UP 20000130 EW 199445 FS OS STAB
 TIEN Resist compositions for circuit boards.
 TIDE Resistzusammensetzungen fuer gedruckte Schaltungen.
 TIFR Compositions formant reserve pour circuits imprimes.
 IN Kawade, Masato, c/o Ividen Co., Ltd., 1-1, Kitaka, Ibigawa-cho, Ibi-gun,
 Gifu, JP;
 Asai, Motoo, c/o Ividen Co., Ltd., 1-1, Kitaka, Ibigawa-cho, Ibi-gun,
 Gifu, JP
 PA IBIDEN CO, LTD., 1, Kanda-cho 2-chome, Ogaki-shi Gifu 503, JP
 PAN 473321
 AG Patentanwaelte Gruenecker, Kinkeldey, Stockmair & Partner,
 Maximilianstrasse 58, D-80538 Muenchen, DE
 AGN 100721
 OS ESP1994079 EP 0623852 A1 941109
 SO Wila-EPZ-1994-H45-T2a
 DT Patent
 LA Anmeldung in Englisch; Veroeffentlichung in Englisch
 DS R DE; R GB; R NL
 PIT EPA1 EUROPAEISCHE PATENTANMELDUNG
 PI EP 623852 A1 19941109
 OD 19941109
 AI EP 1994-107156 19940506
 PRAI JP 1993-106406 19930507

GRANTED PATENT - ERTEILTES PATENT - BREVET DELIVRE

AN 623852 EUROPATFULL ED 19981101 EW 199843 FS PS
 TIEN Resist compositions for circuit boards.
 TIDE Resistzusammensetzungen fuer gedruckte Schaltungen.
 TIFR Compositions formant reserve pour circuits imprimes.
 IN Kawade, Masato, c/o Ividen Co., Ltd., 1-1, Kitaka, Ibigawa-cho, Ibi-gun,
 Gifu, JP;
 Asai, Motoo, c/o Ividen Co., Ltd., 1-1, Kitaka, Ibigawa-cho, Ibi-gun,
 Gifu, JP
 PA IBIDEN CO, LTD., 1, Kanda-cho 2-chome, Ogaki-shi Gifu 503, JP
 PAN 473321
 AG Gruenecker, Kinkeldey, Stockmair & Schwanhaeusser Anwaltssozietaet,
 Maximilianstrasse 58, 80538 Muenchen, DE
 AGN 100721
 OS EPB1998057 EP 0623852 B1 981021
 SO Wila-EPS-1998-H43-T2
 DT Patent

LA Anmeldung in Englisch; Veroeffentlichung in Englisch
 DS R DE; R GB; R NL
 PIT EPB1 EUROPAEISCHE PATENTSCHRIFT
 PI EP 623852 B1 19981021
 OD 19941109
 AI EP 1994-107156 19940506
 PRAI JP 1993-106406 19930507
 REP DE 3717199 A US 5175060 A
 REN PATENT ABSTRACTS OF JAPAN vol. 014, no. 001 (P-985) 8 January
 1990 &
 JP-A-01253730 (IBIDEN CO LTD) 11 October 1989
 ABEN A resist composition having an excellent heat resistance and capable of
 sufficiently withstanding to an alkali bath at pH of not less than 14
 and a bath temperature of 80.degree.C is provided without degrading
 photosensitive properties by using an uncured novolac type epoxy resin,
 a part of epoxy group of which is acrylated, as a resin component of a
 photosensitive resin matrix and adding an imidazole curing agent.
 <image>

L3 ANSWER 17 OF 35 PROMT COPYRIGHT 2000 Gale Group

AN 1998:149751 PROMT
 TI Advanced Viral Research Corp. Announces Extension of Research Agreement
 with National Cancer Institute
 SO PR Newswire, (24 Mar 1998) pp. 0324NYTU003.
 LA English
 WC 325
 FULL TEXT IS AVAILABLE IN THE ALL FORMAT
 AB YONKERS, N.Y., March 24 /PRNewswire/ -- Advanced Viral Research Corp.
 (OTC Bulletin Board: ADVR) today announced that its Materials Transfer
 Agreement-Cooperative Research and Development Agreement (MTA-CRADA)
 with
 the National Cancer Institute (NCI) for research with ADVR's flagship
 drug, Reticulose, has been extended for one year, beginning
 March 4, 1998 and ending March 3, 1999.
 Reticulose is a non-toxic immunomodulator that has been shown to
 have a broad spectrum of antiviral therapeutic effects in patients. At
 the NCI, Reticulose is being used to study the basic mechanisms
 of immune responses. This scientific research is led by Dr. Howard Young,
 Section Chief in the Laboratory of Experimental Immunology at the NCI, an
 expert on interferon-gamma. Using kidney tumor model systems, Dr. Young
 is investigating the anti-tumor activity of Reticulose. In
 addition, Dr. Young and his colleagues will study the effects of
 Reticulose on inflammation associated with rheumatoid
 arthritis.
 "The extension of this collaborative agreement between Advanced Viral
 Research Corp. and one of the premier immunology research laboratories is
 an important event. We expect these research efforts to provide new
 insights into the therapeutic potentials, and uses of Reticulose
 while adding to our basic understanding of the workings of the immune
 system," stated Dr. Shalom Z. Hirschman, President and Chief Executive
 Officer of Advanced Viral Research Corp.
 This news release contains forward-looking statements that involve risks
 and uncertainties, including risks associated with clinical development,
 regulatory approvals, including application to the FDA, product
 commercialization and other risks described from time to time in the SEC
 reports filed by ADVR. Reticulose is not approved by the U.S.
 Food and Drug Administration or any comparable agencies of any other
 countries.

SOURCE: Advanced Viral Research Corp.

-0- 03/24/98
 /CONTACT: Stephanie Brooks or Valerie Itkin, both of SCIENS WorldWide,
 for ADVR, 212-771-5500/
 # (ADVR)
 CO: Advanced Viral Research Corporation, National Cancer Institute
 ST: New York
 IN: MTC
 SU:
 LR-KE
 -- NYTU003 --
 2497 03/24/98 07:30 EST http://www.prnewswire.com
 THIS IS THE FULL TEXT: COPYRIGHT 1998 PR Newswire Association,
 Inc.

L3 ANSWER 18 OF 35 PROMT COPYRIGHT 2000 Gale Group

AN 1999:519129 PROMT
 TI SECTION 2: PRESS ACCESSORIES & SUPPLIES.
 SO Printing Impressions, (July 1997) Vol. 40, No. 2, pp. 84(1).
 ISSN: 0032-860X.
 PB North American Publishing Company
 DT Newsletter
 LA English
 WC 21712
 FULL TEXT IS AVAILABLE IN THE ALL FORMAT
 AB Blankets: Printing Press
 THIS IS THE FULL TEXT: COPYRIGHT 1997 North American Publishing Company

L3 ANSWER 19 OF 35 PROMT COPYRIGHT 2000 Gale Group

AN 1999:806188 PROMT
 TI Categorical Listing of Suppliers.
 SO Shopping Center World, (30 Sep 1997) Vol. 26, No. 10, pp. 4.
 ISSN: 0049-0393.
 PB Intertec Publishing Corporation, A PRIMEDIA Co.
 DT Newsletter
 LA English
 WC 123083
 FULL TEXT IS AVAILABLE IN THE ALL FORMAT
 AB Accounting Audits
 THIS IS THE FULL TEXT: COPYRIGHT 1997 Intertec Publishing Corporation, A PRIMEDIA Co.

Subscription: \$68.00 per year. Published monthly.

L3 ANSWER 20 OF 35 EUROPATFULL COPYRIGHT 2000 WILA

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

AN 802456 EUROPATFULL ED 19971102 EW 199743 FS OS
 TIEN Resist compositions for circuit boards.
 TIDE Resistzusammensetzungen fuer Leiterplatten.
 TIFR Compositions formant reserve pour plaquettes a circuits.
 IN Kawade, Masato, c/o Ividen Co., Ltd., 1-1, Kitaka, Ibigawa-cho, Ibi-gun, Gifu, JP;
 Asai, Motoo, c/o Ividen Co., Ltd., 1-1, Kitaka, Ibigawa-cho, Ibi-gun, Gifu, JP
 PA IBIDEN CO, LTD., 1, Kanda-cho 2-chome, Ogaki-shi Gifu 503, JP
 PAN 473321
 AG Gruenecker, Kinkeldey, Stockmair & Schwanhaeusser Anwaltssozietat, Maximilianstrasse 58, 80538 Muenchen, DE
 AGN 100721
 OS ESP1997064 EP 0802456 A1 971022
 SO Wila-EPZ-1997-H43-T2a
 DT Patent
 LA Anmeldung in Englisch; Veroeffentlichung in Englisch
 DS R DE; R GB; R NL
 PIT EPA1 EUROPAEISCHE PATENTANMELDUNG
 PI EP 802456 A1 19971022
 OD 19971022
 AI EP 1997-110145 19940506
 PRAI JP 1993-106406 19930507
 RLI EP 623852 DIV
 ABEN A resist composition having an excellent heat resistance and capable of sufficiently withstanding to an alkali bath at pH of not less than 14 and a bath temperature of 80.degree.C is provided without degrading photosensitive properties by using an uncured novolac type epoxy resin, a part of epoxy group of which is acrylated, as a resin component of a photosensitive resin matrix and adding an imidazole curing agent.
 <image>

L3 ANSWER 21 OF 35 EUROPATFULL COPYRIGHT 2000 WILA

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

AN 771800 EUROPATFULL ED 19970604 EW 199719 FS OS
 TIEN Dioxino derivatives and their use as dopamine agonists.
 TIDE Dioxinoderivate und ihre Verwendung als Dopamine-Agonisten.
 TIFR Derives dioxino et leur utilisation comme agonistes de la dopamine.
 IN Stack, Gary Paul, 25 Brookfield Lane, Ambler, Pennsylvania, 19002, US;

Mewshaw, Richard Eric, 21 Boxwood Drive, Princeton, New Jersey, 08540, US;
 Bravo, Byron Abel, 29-05 Fox Run Drive, Plainsboro, New Jersey 08536, US;
 Kang, Young Hee, 324 Andover Place, Robbinsville, New Jersey, 08691, US
 PA AMERICAN HOME PRODUCTS CORPORATION, Five Giralda Farms, Madison, New Jersey 07940-0874, US
 PAN 201462
 AG Connelly, Michael John, c/o Patent Department Wyeth Laboratories Huntercombe Lane South Taplow, Maidenhead Berkshire SL6 0PH, GB
 AGN 52262
 OS ESP1997025 EP 0771800 A2 970507
 SO Wila-EPZ-1997-H19-T1a
 DT Patent
 LA Anmeldung in Englisch; Veroeffentlichung in Englisch
 DS R AT; R BE; R CH; R DE; R DK; R ES; R FI; R FR; R GB; R GR; R IE; R IT;
 R LI; R LU; R NL; R PT; R SE
 PIT EPA2 EUROPAEISCHE PATENTANMELDUNG
 PI EP 771800 A2 19970507
 OD 19970507
 AI EP 1996-307616 19961022
 PRAI US 1995-7283 19951106
 US 1996-730267 19961015

ABEN The compounds of formula I: <image> wherein R.sup1. and R.sup2. are, independently, hydrogen, alkyl, phenyl or benzyl; or R.sup1. and R.sup2., taken together, are benzylidene optionally substituted with R.sup3. as defined below or alkylidene, or R.sup1. and R.sup2., taken together with the carbon to which they are attached, form a carbonyl moiety or a cycloalkyl group; R.sup3. is hydrogen, hydroxy, halo, trifluoromethyl, trifluoromethoxy, alkyl, alkoxy, aralkoxy, alkanoyloxy, amino, mono- or di-alkylamino, alkanamido or alkanesulfonamido; R.sup4. is hydrogen or alkyl; m is an integer 0, 1 or 2; n is an integer from 0 to 6, inclusive; Z is hydrogen, hydroxy, alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, polycyclo-alkyl, phenyl optionally substituted with R.sup3. as defined above, phenoxy optionally substituted with R.sup3. as defined above or naphthyl optionally substituted with R.sup3. as defined above or naphthyloxy optionally substituted with R.sup3. as defined above, heteroaryl or heteroaryloxy, in which the heterocyclic ring of the heteroaryl or heteroaryloxy group is selected from thiophene, furan, pyridine, pyrazine, pyrimidine, indole, indazole, imidazole, chroman, coumarin, carbostyryl, quinoline, benzisoxazole, benzoxazole, pyrazole, pyrrole, thiazole, oxazole, or isoxazole and the heterocyclic ring is optionally substituted by R.sup3. as defined above; or a pharmaceutically acceptable salt thereof, are useful in treating disorders of the dopaminergic system.

L3 ANSWER 22 OF 35 EUROPATFULL COPYRIGHT 2000 WILA

GRANTED PATENT - ERTEILTES PATENT - BREVET DELIVRE

AN 504063 EUROPATFULL ED 19970710 EW 199726 FS PS
 TIEN Transceiver for the simultaneous bidirectional baseband transmission of data.
 TIDE Sender-Empfaenger fuer gleichzeitige, bidirektionelle Datenuebertragung im Basisband.
 TIFR Emetteur-recepteur pour la transmission bidirectionelle simultanee de donnees en bande de base.
 IN Marbot, Roland, 121, avenue de Malakoff, F-75116 Paris, FR
 PA BULL S.A., 68, route de Versailles, 78430 Louveciennes, FR
 PAN 244471
 AG Colombe, Michel et al, Direction de la Propriete Intellectuelle BULL SA Poste courrier:LV 59C18 68 route de Versailles, 78430 Louveciennes, FR
 AGN 46243
 OS EPB1997041 EP 0504063 B1 970625
 SO Wila-EPS-1997-H26-T2
 DT Patent
 LA Anmeldung in Franzoesisch; Veroeffentlichung in Franzoesisch
 DS R AT; R BE; R CH; R DE; R ES; R FR; R GB; R IT; R LI; R NL; R SE
 PIT EPB1 EUROPAEISCHE PATENTSCHRIFT
 PI EP 504063 B1 19970625
 OD 19920916
 AI EP 1992-400662 19920312
 PRAI FR 1991-3127 19910314
 REP EP 220626 A US 3700831 A
 US 3909559 A

L3 ANSWER 23 OF 35 EUROPATFULL COPYRIGHT 2000 WILA
PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

AN 745673 EUROPATFULL ED 19970307 EW 199649 FS OS
TIEN Catalytic antibody regulated prodrug therapy.
TIDE Katalytische Antikörper-regulierte Prodrugtherapie.
TIFR Therapie promedicamenteuse regulee par des anticorps catalytiques.
IN Blackburn, George Michael, Dep. of Chemistry, University of Sheffield,
Sheffield, GB-S37 HF, GB;
Wentworth, Paul, Dep. of Molecular Biology MB34, Scripps Res. Inst.,
10666 North Torrey Pines Road, La Jolla, California 92037, US
PA ZENECA LIMITED, 15 Stanhope Gate, London W1Y 6LN, GB
PAN 1579441
AG Giles, Allen Frank et al, Intellectual Property Department ZENECA
Pharmaceuticals Alderley Park, Macclesfield, Cheshire SK10 4TG, GB
AGN 80171
OS ESP1996065 EP 0745673 A2 961204
SO Wila-EPZ-1996-H49-T1a
DT Patent
LA Anmeldung in Englisch; Veroeffentlichung in Englisch
DS R CH; R DE; R FR; R GB; R IT; R LI
PIT EPA2 EUROPAEISCHE PATENTANMELDUNG
PI EP 745673 A2 19961204
OD 19961204
AI EP 1996-303643 19960522
PRAI GB 1995-10830 19950527

ABEN Catalytic antibodies capable of catalysing activation of a carbamate
(-O-CO-NH-) containing prodrug suitable for Antibody Directed Abzyme
Prodrug Therapy (ADAPT) by catalysing breakdown of the prodrug at the
carbamate position by a non-spontaneous reaction mechanism. The
non-spontaneous reaction preferably has a B.subAc.2 mechanism and the
prodrug is a preferably a nitrogen mustard aryl carbamate. The invention
also includes relevant immunogens, screens for catalytic activity using
short transition state analogues and ADAPT systems.

L3 ANSWER 24 OF 35 EUROPATFULL COPYRIGHT 2000 WILA
PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

AN 693489 EUROPATFULL ED 19970108 EW 199604 FS OS
TIEN Heterocyclic tachykinin receptor antagonists.
TIDE Heterocyclische Tachykinin-Rezeptor-Antagonisten.
TIFR Antagonistes heterocycliques du recepteur des tachykinines.
IN Cho, Sung-Yong Stephen, 49 Showers Drive No. B451, Mountain View,
California 94040, US;
Copp, James Densmore, 2031 Foxmoor Terrace, Greenwood, Indiana 46143,
US;
Ginah, Francis Orenyeno, 2225 Broadway, Indianapolis, Indiana 46205, US;
Hansen, Guy Joe, 5235 Camden, Indianapolis, Indiana 46227, US;
Hipskind, Philip Arthur, 3660 South Farmstone Circle, New Palestine,
Indiana 46163, US;
Huff, Bret Eugene, 201 Oak Hill Lane, Mooresville, Indiana 46158, US;
Martinelli, Michael John, 5242 Wilton Wood Court, Indianapolis, Indiana
46254, US;
Staszak, Michael Alexander, 4515 North Lakeridge Drive, Indianapolis,
Indiana 46234, US;
Tharp-Taylor, Roger William, 14965 Allisonville Road, Noblesville,
Indiana 46060, US
PA ELI LILLY AND COMPANY, Lilly Corporate Center, Indianapolis, Indiana
46285, US
PAN 204942
AG Tapping, Kenneth George et al, Lilly Industries Limited European Patent
Operations Erl Wood Manor, Windlesham Surrey GU20 6PH, GB
AGN 52302
OS ESP1996005 EP 0693489 A1 960124
SO Wila-EPZ-1996-H04-T1a
DT Patent
LA Anmeldung in Englisch; Veroeffentlichung in Englisch
DS R AT; R BE; R CH; R DE; R DK; R ES; R FR; R GB; R GR; R IE; R IT; R
LI;
R LU; R NL; R PT; R SE
PIT EPA1 EUROPAEISCHE PATENTANMELDUNG
PI EP 693489 A1 19960124
OD 19960124
AI EP 1995-304750 19950707

PRAI US 1994-271708 19940712
ABEN This invention provides the novel compound of the following formula
<image> having the chemical name (R)-3-(1H-indol-3-yl)-1-[N-(2-
methoxybenzyl)acetylamino]-2-[N-(2-(4-(piperidin-1-yl)piperidin-1-
yl)acetyl)amino]propane dihydrochloride trihydrate.

L3 ANSWER 25 OF 35 EUROPATFULL COPYRIGHT 2000 WILA
GRANTED PATENT - ERTEILTES PATENT - BREVET DELIVRE

AN 509769 EUROPATFULL ED 19970307 EW 199637 FS PS
TIEN Heterocyclic amides having HLE inhibiting activity.
TIDE HLE-inhibierende heterozyklische Amide.
TIFR Amides heterocycliques ayant une activite inhibante de HLE.
IN Bernstein, Peter Robert, ICI Americas Inc, Concord Pike & New Murphy
Road, Wilmington DE, US;
Shaw, Andrew, ICI Americas Inc, Concord Pike & New Murphy Road,
Wilmington DE, US;
Thomas, Royston Martin, ICI Americas Inc, Concord Pike & New Murphy
Road, Wilmington DE, US;
Wolanin, Donald John, ICI Americas Inc, Concord Pike & New Murphy Road,
Wilmington DE, US;
Warner, Peter, Alderley Park, Macclesfield, Cheshire SK10 4TG, GB
PA ZENECA LIMITED, 15 Stanhope Gate, London W1Y 6LN, GB
PAN 1579441
AG Smith, Stephen Collyer et al, Intellectual Property Department ZENECA
Pharmaceuticals Mereside Alderley Park, Macclesfield Cheshire SK10 4TG,
GB
AGN 43083
OS EPB1996057 EP 0509769 B1 960911
SO Wila-EPS-1996-H37-T1
DT Patent
LA Anmeldung in Englisch; Veroeffentlichung in Englisch
DS R DE; R FR; R GB; R IT
PIT EPB1 EUROPAEISCHE PATENTSCHRIFT
PI EP 509769 B1 19960911
OD 19921021
AI EP 1992-303358 19920415
PRAI GB 1991-8358 19910418
GB 1991-8357 19910418
GB 1992-5392 19920312
REP EP 189305 A US 4474778 A
REN BIOCHEMISTRY. vol. 25, no. 13, 1 July 1986, EASTON, PA US pages
3760 -
3767 B IMPERIALI AND R H ABELES 'inhibition of serine proteases by
peptidyl fluoromethyl ketones'

L3 ANSWER 26 OF 35 FROSTI COPYRIGHT 2000 LFRA
AN 382293 FROSTI
TI Information - an essential raw material for the food industry.
AU Leadbetter S.
SO European Food and Drink Review, 1995, (Spring), 73-75 (0 ref.)
DT Journal
LA English
SL English
AB New developments in information technology are discussed. On-line access
to databases either directly through the database producer or through a
public access host is described. The use of CD-ROM for the bulk of
everyday research with on-line access for the most current and up-to-date
material is recommended. It is emphasised that the food industry needs
to be in touch with key technical, legal and commercial advances quickly
and simply. The ways in which developments in information technology can
simplify the complexities of international food legislation, harness
information for successful product R&D and realise
the strategic benefits of food market intelligence are discussed. The
series of databases produced by the Leatherhead Food RA is
listed.

L3 ANSWER 27 OF 35 IFIPAT COPYRIGHT 2000 IFI
AN 2459021 IFIPAT;IFIUDB;IFICDB
TI SELF-COHERENCE RESTORING SIGNAL EXTRACTION AND
ESTIMATION OF SIGNAL
DIRECTION OF ARRIVAL
INF Agee, Brian G, San Jose, CA
Gardner, William A, Yountville, CA
Schell, Stephan V, Livermore, CA
IN Agee Brian G; Gardner William A; Schell Stephan V

PAF The Regents of the University of California, Oakland, CA
 PA California, University of Regents (13234)
 EXNAM Black, Thomas G
 EXNAM Zanelli, Michael
 AG O'Banion, John P
 PI US 5299148 19940329 (CITED IN 006 LATER PATENTS)
 AI US 1990-526840 19900522
 XPD 29 Mar 2011
 RLI US 1988-264256 19881028 CONTINUATION-IN-PART
 ABANDONED
 FI US 5299148 19940329
 DT UTILITY
 FS ELECTRICAL
 GOV1 This invention was made with Government support under Grant/Contract No. MIP-88-12902 awarded by the National Science Foundation. Additional support was provided by the Army Research Office under contract No. DAAL03-89-C-0035 through Statistical Signal Processing, Inc. The Government has certain rights in this invention.
 MRN 005561 MFN: 0728
 CLMN 41
 GI 16 Drawing Sheet(s), 19 Figure(s).
 AB A processor and method for extracting or estimating directions of arrival of signals from a received data vector $x(t)$ which has been corrupted by interfering signals and noise is described. The processor extracts signals by forming the scalar product of $x(t)$ and a weight vector which is chosen such that the spectral self-coherence or conjugate spectral self-coherence of the processor output is maximized. The processor estimates the directions of arrival of signals by spectral self-coherence-selective performance surfaces for maxima.

L3 ANSWER 28 OF 35 MEDLINE
 AN 88116869 MEDLINE
 DN 88116869
 TI Quantitative evaluation of regional myocardial blood flow by digital subtraction angiography: correlations with exercise electrocardiography and Tl-201 myocardial scintigraphy.
 AU Ikeda H; Shibao K; Yamaguchi R; Yoh M; Shimamatsu M; Hiyanuta K; Itaya K;
 Ohkita Y; Sugi K; Koga Y; et al
 CS Third Department of Internal Medicine, Kurume University, School of Medicine..
 SO JOURNAL OF CARDIOGRAPHY. SUPPLEMENT, (1987) 12 81-9.
 Journal code: AKN. ISSN: 0386-2887.
 CY Japan
 DT Journal; Article; (JOURNAL ARTICLE)
 LA Japanese
 FS Priority Journals
 EM 198805
 AB We previously reported that the contrast disappearance half-life ($T_{1/2}$) derived by the computerized washout analysis of digital subtraction coronary arteriograms provides a useful index for quantitatively evaluating regional myocardial blood flow. In the present study, we further evaluated the clinical usefulness of $T_{1/2}$, comparing it with exercise electrocardiography and exercise thallium-201 myocardial scintigraphy. The study subjects consisted of 25 patients with angina pectoris and 14 patients with normal coronary arteries. Following the manual injection of contrast media into the left anterior descending coronary artery (LAD), a time-density curve was generated in the sectors of the myocardium which were perfused by the LAD and the $T_{1/2}$ was calculated. $T_{1/2}$ values correlated closely with double product ($r = -0.73$). They were significantly greater in patients with exercise-induced ST depression (8.3 ± 1.0 vs 5.8 ± 0.7 , p less than 0.005). In addition, there was a good correlation between $T_{1/2}$ values and washout ratio as determined by exercise thallium-201 myocardial scintigraphy, with $r = -0.83$. Although $T_{1/2}$ values were within the normal range (mean \pm 2SD of control subjects) in all patients with LAD stenosis of 50 percent or less, these values were abnormally increased, exceeding the normal range, in 11 of the 12 patients with stenosis of 90 percent or more. Compared with exercise electrocardiography, $T_{1/2}$ values were abnormally prolonged in 11 of the 13 patients with exercise-induced ST depression. Compared with exercise thallium-201 myocardial scintigraphy, $T_{1/2}$ values were abnormally prolonged in seven of the nine patients with transient perfusion defects.(ABSTRACT TRUNCATED AT 250 WORDS)

L3 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2000 ACS
 AN 1985:489646 CAPLUS
 DN 103:89646
 TI Exact uniqueness and multiplicity criteria for, and steady state and

dynamic behavior of an isothermal CSTR with general autocatalytic reactions. No product R in feed
 AU Chi, Jung Chang
 CS Dep. Chem. Eng., Tamkang Univ., Tamsui, 251, Taiwan
 SO J. Chin. Inst. Chem. Eng. (1985), 16(2), 133-44
 CODEN: JCICAP; ISSN: 0368-1653
 DT Journal
 LA English
 AB An isothermal, continuous-flow, stirred-tank reactor (CSTR) is analyzed in the case of an autocatalytic reaction of the general type $A \xrightarrow{k_1} R$. $\alpha R + P \xrightarrow{k_2} R$ without feeding R. Exact crit. for uniqueness and multiplicity of steady states as well as stable steady states are established. Steady-state behavior with changing Damkohler no. and dynamic reactor behavior on the phase plane are discussed. The max. no. of steady-state solns. is 4 with $m < 1$ and 3 with $m \geq 1$. The system can have at most 2 stable steady states. All stable steady states are nodes, all unstable steady states are saddle points, and no limit cycles exist. Graphs showing regions of uniqueness and multiplicity of stable steady states in parameter space are given.

L3 ANSWER 30 OF 35 COPYRIGHT 2000 PJB
 AN 83:9093 PHIN
 DN C00009784
 DED 24 Jun 1983
 TI CooperBiomedical's share offer
 SO Clinica (1983) No. 70 p8
 DT Newsletter
 FS FULL

L3 ANSWER 31 OF 35 IFIPAT COPYRIGHT 2000 IFI
 AN 0880300 IFIPAT;IFIUDB;IFICDB
 TI CAPACITANCE MULTIPLIER AND FILTER SYNTHESIZING NETWORK
 INF Fletcher, James C Administrator of the National Aeronautics and Space Administration with respect to an invention by, , Scottsdale, AZ, 85251
 Kline, Arthur J, 6453 E Monta Rosa St, Scottsdale, AZ, 85251
 IN FLETCHER J; KLINE A
 PAF Unassigned
 PA US OF AMERICA NASA ADMINISTRATOR OF (86504)
 EXNAM Kaufman, Nathan
 AG Manning, John R
 McCaul, Paul F
 Mott, Monte F
 PI US 3831117 19740820 (CITED IN 016 LATER PATENTS)
 AI US 1972-306652 19721115
 XPD 20 Aug 1991
 FI US 3831117 19740820
 DT UTILITY
 FS ELECTRICAL
 CLMN 5
 GI 1 Drawing Sheet(s), 4 Figure(s).
 AB A circuit using a differential amplifier multiplies the capacitance of a discrete integrating capacitor by $(R_1 + R_2)/R_2$ where R_1 and R_2 are values of discrete resistor coupling an input signal e_i to the amplifier inputs. The output e_o of the amplifier is fed back and added to the signal coupled by the resistor R_2 to the amplifier through a resistor of value R_1 . A discrete resistor R_x may be connected in series for a lag filter and a discrete resistor may be connected in series with the capacitor for a lead-lag filter. Voltage dividing resistors R_a and R_b may be included in the feedback circuit of the amplifier output e_o to independently adjust the overall circuit gain e_i/e_o .

L3 ANSWER 32 OF 35 MEDLINE
 AN 73070738 MEDLINE
 DN 73070738
 TI [Diffuse lymphoreticulosis of the orbit].
 La lympho-reticulose diffuse de l'orbite.
 AU Cernea P; Dobrescu G
 SO ANNALES D OCULISTIQUE, (1972 Jul) 205 (7) 775-86.
 Journal code: SOU. ISSN: 0003-4371.
 CY France
 DT Journal; Article; (JOURNAL ARTICLE)
 LA French
 FS Priority Journals
 EM 197304

L3 ANSWER 33 OF 35 MEDLINE

AN 69267885 MEDLINE

DN 69267885

TI [Generalized follicular mucinosis revealing cutaneous and bronchopulmonary histiomonocytic reticulosis oa case].

Mucinose folliculaire generalisee revelatrice d'une reticulose histiomonocyttaire `a localisations cutanees et broncho-pulmonaires. Epilogue d'une observation.

AU Grosshans E; Bohner C; Weitzenblum E; Rousselot P; Maleville J; Basset A
SO SEMAINE DES HOPITAUX, (1969 May 14) 45 (23) 1626-33.

Journal code: ULD. ISSN: 0037-1777.

CY France

DT Journal; Article; (JOURNAL ARTICLE)

LA French

FS Priority Journals

EM 196911

L3 ANSWER 34 OF 35 MEDLINE

AN 70201004 MEDLINE

DN 70201004

TI [Giant-cell multicentric histiocytic reticulosis].

Reticulose histiocyttaire multi-centrique giganto-cellulaire.

AU Stewart W M; Metayer; Lecroq C; Lauret P; Chegaray E

SO BULLETIN DE LA SOCIETE FRANCAISE DE DERMATOLOGIE ET DE SYPHILIGRAPHIE,

(1969) 76 (6) 814-7.

Journal code: COG. ISSN: 0049-1071.

CY France

DT Journal; Article; (JOURNAL ARTICLE)

LA French

FS Priority Journals

EM 197009

L3 ANSWER 35 OF 35 MEDLINE

AN 69178108 MEDLINE

DN 69178108

TI [Histiocytic reticulosis in infants or Letterer-Siwe disease. (Clinical and therapeutical study)].

La reticulose histiocyttaire du nourrisson ou maladie de Letterer-Siwe. (Etude clinique et therapeutique).

AU Marie J; Hennequet A; Leveque B; Debauchez C; Desbois C; Watchi J M

SO ANNALES DE PEDIATRIE, (1968 Nov 2) 15 (11) 681-96.

Journal code: SUC. ISSN: 0066-2097.

CY France

DT Journal; Article; (JOURNAL ARTICLE)

LA French

EM 196908

=> file uspatfull

=> s 11

L4 128 (RETICULOSE OR PRODUCT (W) "R") AND (RHEUMATOID OR RA)

=> s 14 and arthritis

13839 ARTHRITIS

L5 80 L4 AND ARTHRITIS

=> d 1-80 bib ab

L5 ANSWER 1 OF 80 USPATFULL

AN 2000:31435 USPATFULL

TI Fluorinated butyric acids and their derivatives as inhibitors of matrix metalloproteinases

IN Roth, Bruce David, Plymouth, MI, United States

O'Brien, Patrick Michael, Stockbridge, MI, United States

Sliskovic, Drago Robert, Saline, MI, United States

PA Warner-Lambert Company, Ann Arbor, MI, United States (U.S. corporation)

PI US 6037361 20000314

AI US 1998-36751 19980309 (9)

DT Utility

EXNAM Primary Examiner: Kight, John; Assistant Examiner: Covington, Raymond

LREP Merchant & Gould P.C.

CLMN Number of Claims: 32

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 1247

AB Fluorinated butyric acid compounds and derivatives are described as well as acid methods for the preparation and pharmaceutical compositions of

same, which are useful as inhibitors of matrix metalloproteinases, particularly gelatinase A (72 kD gelatinase) and stromelysin-1, and also collagenase, matrilysin, and MMP-13, and for the treatment of multiple sclerosis, atherosclerotic plaque rupture, aortic aneurism, heart failure, restenosis, periodontal disease, corneal ulceration, treatment of burns, decubital ulcers, wound healing, cancer, inflammation, pain, arthritis, or other autoimmune or inflammatory disorders dependent upon tissue invasion by leukocytes or other activated migrating cells, acute and chronic neurodegenerative disorders including stroke, head trauma, spinal cord injury, Alzheimer's disease, amyotrophic lateral sclerosis, cerebral amyloid angiopathy, AIDS, Parkinson's disease, Huntington's disease, prion diseases, myasthenia gravis, and Duchenne's muscular dystrophy.

L5 ANSWER 2 OF 80 USPATFULL

AN 2000:9904 USPATFULL

TI Heterocyclic compounds

IN Hohlweg, Rolf, Kvistgaard, Denmark

PA Novo Nordisk A/S, Bagsvaerd, Denmark (non-U.S. corporation)

PI US 6017915 20000125

AI US 1998-79599 19980515 (9)

RLI Division of Ser. No. US 1996-715665, filed on 18 Sep 1996, now patented, Pat. No. US 5753678

PRAI DK 1995-1040 19950919

DK 1995-1041 19950919

DT Utility

EXNAM Primary Examiner: Kight, John; Assistant Examiner: Aislakh, Charanjit S.

LREP Zelson, Steve T.; Rozek, Carol E.

CLMN Number of Claims: 5

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 890

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel N-substituted amino alcohols, amino acids and acid derivatives thereof in which a substituted alkyl chain forms part of the N-substituent or salts thereof, to methods for their preparation, to compositions containing them, and to their use for the clinical treatment of painful, hyperalgesic and/or inflammatory conditions in which C-fibers play a pathophysiological role by eliciting neurogenic pain or inflammation.

L5 ANSWER 3 OF 80 USPATFULL

AN 1999:137513 USPATFULL

TI 1-substituted, 2-substituted 1H-imidazo[4,5-c] quinolin-4-amines

IN Gerster, John F., Woodbury, MN, United States

Crooks, Stephen L., Mahtomedi, MN, United States

Lindstrom, Kyle J., Houlton, WI, United States

PA 3M Innovative Properties Company, St. Paul, MN, United States (U.S. corporation)

PI US 5977366 19991102

AI US 1998-60010 19980414 (9)

RLI Division of Ser. No. US 1997-789264, filed on 28 Jan 1997, now patented, Pat. No. US 5741909 which is a division of Ser. No. US 1994-353802, filed on 12 Dec 1994, now patented, Pat. No. US 5605899 which is a division of Ser. No. US 1992-938295, filed on 28 Aug 1992, now patented, Pat. No. US 5389640 which is a continuation-in-part of Ser. No. US 1992-838475, filed on 19 Feb 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-687326, filed on 18 Apr 1991, now abandoned which is a continuation-in-part of Ser. No. US 1991-662926, filed on 1 Mar 1991, now abandoned

DT Utility

EXNAM Primary Examiner: Rotman, Alan L.

LREP Howard, MarySusan; Ringsred, Ted K.; Sprague, Robert W.

CLMN Number of Claims: 2

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 2303

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB 1-substituted, 2-substituted 1H-imidazo[4,5-c]-quinolin-4-amines are disclosed. These compounds function as antiviral agents, they induce biosynthesis of interferon, and they inhibit tumor formation in animal models. This invention also provides intermediates for preparing such compounds, pharmaceutical compositions containing such compounds, and pharmacological methods of using such compounds.

L5 ANSWER 4 OF 80 USPATFULL

AN 1999:132809 USPATFULL

TI Heterocyclic compounds

IN Hohlweg, Rolf, Kvistgaard, Denmark
 PA Novo Nordisk A/S, Bagsvaerd, Denmark (non-U.S. corporation)
 PI US 5972925 19991026
 AI US 1997-922977 19970904 (8)
 RLI Division of Ser. No. US 1996-715665, filed on 18 Sep 1996
 PRAI DK 1995-1040 19950919
 DK 1995-1041 19950919
 DT Utility
 EXNAM Primary Examiner: Rotman, Alan L.; Assistant Examiner: Aulakh, Charanjit S.
 LREP Zelson, Steve T.; Lambiris, Elias; Rozek, Carol E.
 CLMN Number of Claims: 14
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN.CNT 918
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB The present invention relates to novel N-substituted amino alcohols, amino acids and acid derivatives thereof in which a substituted alkyl chain forms part of the N-substituent or salts thereof, to methods for their preparation, to compositions containing them, and to their use for the clinical treatment of painful, hyperalgesic and/or inflammatory conditions in which C-fibers play a pathophysiological role by eliciting neurogenic pain or inflammation.

L5 ANSWER 5 OF 80 USPATFULL
 AN 1999:128543 USPATFULL
 TI Tricyclic compounds for the inhibition of the ICE/ced-3 protease family of enzymes
 IN Karanewsky, Donald S., Escondido, CA, United States
 Linton, Steven D., San Diego, CA, United States
 PA Idun Pharmaceuticals, Inc., La Jolla, CA, United States (U.S. corporation)
 PI US 5968927 19991019
 AI US 1997-928990 19970912 (8)
 RLI Continuation-in-part of Ser. No. US 1996-710621, filed on 20 Sep 1996, now abandoned
 DT Utility
 EXNAM Primary Examiner: Raymond, Richard L.; Assistant Examiner: Kifle, Bruck
 LREP Seed and Berry LLP
 CLMN Number of Claims: 48
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN.CNT 2053
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB This invention is directed to novel tricyclic ICE/ced-3 family inhibitor compounds. The invention is also directed to pharmaceutical compositions of such tricyclic compounds, plus the use of such compositions in the treatment of patients suffering inflammatory, autoimmune and neurodegenerative diseases, and for the prevention of ischemic injury.

L5 ANSWER 6 OF 80 USPATFULL
 AN 1999:110488 USPATFULL
 TI Therapeutic compound-fatty acid conjugates
 IN Whittaker, Robert George, West Pymble, Australia
 Bender, Veronika Judith, Cremorne, Australia
 Reilly, Wayne Gerrard, Northmead, Australia
 Moghaddam, Minoo, Killara, Australia
 PA Commonwealth Scientific and Industrial Research Organisation, Campbell, Australia (non-U.S. corporation)
 PI US 5952499 19990914
 WO 9622303 19960725
 AI US 1997-875098 19970925 (8)
 WO 1996-AU15 19960115
 19970925 PCT 371 date
 19970925 PCT 102(e) date
 DT Utility
 EXNAM Primary Examiner: Dees, Jose' G.; Assistant Examiner: Badio, Barbara
 LREP McDermott, Will & Emery
 CLMN Number of Claims: 16
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN.CNT 2128
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB A methotrexate conjugated to 1-3 acyl groups derived from fatty acids. In particular the invention relates to altering the pharmacokinetic profile and mode of delivery of methotrexate by conjugating it to 1.2 or

3 acyl derivatives of fatty acids.

L5 ANSWER 7 OF 80 USPATFULL
 AN 1999:85629 USPATFULL
 TI Inhibitors of metalloproteases, pharmaceutical compositions comprising same and methods of their use
 IN Campbell, David A., San Mateo, CA, United States
 Patel, Dinesh V., Fremont, CA, United States
 Xiao, Xiao-Yi, La Jolla, CA, United States
 PA Affymax Technologies N.V., Greenford, United Kingdom (non-U.S. corporation)
 PI US 5929278 19990727
 AI US 1998-81466 19980519 (9)
 RLI Continuation of Ser. No. US 1995-549345, filed on 27 Oct 1995, now patented, Pat. No. US 5831004 which is a continuation-in-part of Ser. No. US 1995-484255, filed on 7 Jun 1995, now abandoned which is a continuation-in-part of Ser. No. US 1994-329420, filed on 27 Oct 1994, now abandoned
 DT Utility
 EXNAM Primary Examiner: Tsang, Cecilia J.; Assistant Examiner: Delacroix-Muirheid, C.
 LREP Swiss, Gerald F.; Stevens, Lauren L.
 CLMN Number of Claims: 8
 ECL Exemplary Claim: 1
 DRWN 17 Drawing Figure(s); 13 Drawing Page(s)
 LN.CNT 2235
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Disclosed are novel inhibitors of metalloproteases, in particular matrix metalloproteases. The disclosed inhibitors are mercaptoketone and mercaptoalcohol compounds which are useful in pharmaceutical compositions and methods for treating or controlling disease states or conditions which involve tissue breakdown, for example, arthropathy, dermatological conditions, bone resorption, inflammatory diseases, and tumor invasion and in the promotion of wound healing.

L5 ANSWER 8 OF 80 USPATFULL
 AN 1999:78711 USPATFULL
 TI Morpholine and thiomorpholine tachykinin receptor antagonists
 IN Dorn, Conrad P., Plainfield, NJ, United States
 PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
 PI US 5922706 19990713
 AI US 1997-969685 19971113 (8)
 RLI Division of Ser. No. US 1995-525259, filed on 5 Sep 1995, now patented, Pat. No. US 5719147 which is a continuation-in-part of Ser. No. WO 1994-US14497, filed on 13 Dec 1994 And Ser. No. US 1993-169889, filed on 17 Dec 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-61914, filed on 19 May 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-971448, filed on 4 Nov 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-905976, filed on 29 Jun 1992, now abandoned
 DT Utility
 EXNAM Primary Examiner: Grumbling, Matthew V.
 LREP Thies, J. Eric; Rose, David L.
 CLMN Number of Claims: 21
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN.CNT 7932
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Substituted heterocycles of the general structural formula: ##STR1## are tachykinin receptor antagonists useful in the treatment of inflammatory diseases, pain or migraine, asthma and emesis, and calcium channel blockers useful in the treatment of cardiovascular conditions such as angina, hypertension or ischemia.

L5 ANSWER 9 OF 80 USPATFULL
 AN 1999:75625 USPATFULL
 TI Fucose derivatives, drugs containing the same as active ingredient, and intermediates for producing the same
 IN Tsukida, Takahiro, Osaka, Japan
 PA Kanebo, Ltd, Tokyo, Japan (non-U.S. corporation)
 PI US 5919769 19990706
 WO 9715585 19970501
 AI US 1998-51846 19980422 (9)
 WO 1996-JP3081 19961023
 19980422 PCT 371 date
 19980422 PCT 102(e) date
 PRAI JP 1995-303476 19951026
 JP 1996-175487 19960613

DT Utility

EXNAM Primary Examiner: Lambkin, Deborah C.

LREP Merchant, Gould, Smith, Edell, Welter & Schmidt

CLMN Number of Claims: 7

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 3664

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A compound of the formula (I): ##STR1## wherein X.sup.1 is a group of one of the following formulae (1), (2) and (3): ##STR2## R.sup.1 is a branched long chain alkyl group, R.sup.2 is --CONHR.sup.3, a carboxyl group or a hydrogen atom, n is an integer of 0, 1 or 2, and R.sup.3 is a lower alkyl group or a phenyl group, or a pharmaceutically acceptable salt thereof, which is useful as a selectin inhibitor, and can be used in the prophylaxis or treatment of various inflammatory diseases such as inflammatory dermatitis (e.g., atopic dermatitis, contact hypersensitivity, photodermatitis, etc.), autoimmune chronic diseases (e.g. **rheumatoid arthritis**, chronic thyroiditis, etc.), and ischemia-reperfusion injury.

L5 ANSWER 10 OF 80 USPATFULL

AN 1999:72739 USPATFULL

TI Heterocyclic compounds

IN Hohlweg, Rolf, Kvistgaard, Denmark

PA Novo Nordisk A/S, Bagsvaerd, Denmark (non-U.S. corporation)

PI US 5917047 19990629

AI US 1997-957172 19971024 (8)

RLI Division of Ser. No. US 1996-715665, filed on 18 Sep 1996

PRAI DK 1995-1040 19950905

DK 1995-1041 19950905

DT Utility

EXNAM Primary Examiner: Rotman, Alan L.; Assistant Examiner: Aulakh, Charanjit S.

LREP Zelson, Steve T.; Rozek, Carol E.; Lambiris, Elias J.

CLMN Number of Claims: 6

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 905

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel N-substituted amino alcohols, amino acids and acid derivatives thereof in which a substituted alkyl chain forms part of the N-substituent or salts thereof, to methods for their preparation, to compositions containing them, and to their use for the clinical treatment of painful, hyperalgesic and/or inflammatory conditions in which C-fibers play a pathophysiological role by eliciting neurogenic pain or inflammation.

L5 ANSWER 11 OF 80 USPATFULL

AN 1999:72593 USPATFULL

TI Heterocyclic compounds

IN Hohlweg, Rolf, Kvistgaard, Denmark

PA Novo Nordisk A/S, Bagsvaerd, Denmark (non-U.S. corporation)

PI US 5916901 19990629

AI US 1998-79935 19980515 (9)

RLI Division of Ser. No. US 1996-715665, filed on 18 Sep 1996, now patented, Pat. No. US 5753678

PRAI DK 1995-1040 19950919

DK 1995-1041 19950919

DT Utility

EXNAM Primary Examiner: Rotman, Alan L.; Assistant Examiner: Aulakh, Charanjit S.

LREP Zelson, Steve T.; Lambiris, Elias J.; Rozek, Carol E.

CLMN Number of Claims: 9

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 891

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel N-substituted amino alcohols, amino acids and acid derivatives thereof in which a substituted alkyl chain forms part of the N-substituent or salts thereof, to methods for their preparation, to compositions containing them, and to their use for the clinical treatment of painful, hyperalgesic and/or inflammatory conditions in which C-fibers play a pathophysiological role by eliciting neurogenic pain or inflammation.

L5 ANSWER 12 OF 80 USPATFULL

AN 1999:67281 USPATFULL

TI Heterocyclic compounds

IN Hohlweg, Rolf, Kvistgaard, Denmark

PA Novo Nordisk A/S, Bagsvaerd, Denmark (non-U.S. corporation)

PI US 5912262 19990615

AI US 1997-957163 19971024 (8)

RLI Division of Ser. No. US 1996-715665, filed on 18 Sep 1996

PRAI DK 1995-1040 19950919

DK 1995-1041 19950919

DT Utility

EXNAM Primary Examiner: Rotman, Alan L.; Assistant Examiner: Aulakh, Charanjit S.

LREP Zelson, Steve T.; Rozek, Carol E.; Lambiris, Elias J.

CLMN Number of Claims: 11

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 907

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel N-substituted amino alcohols, amino acids and acid derivatives thereof in which a substituted alkyl chain forms part of the N-substituent or salts thereof, to methods for their preparation, to compositions containing them, and to their use for the clinical treatment of painful, hyperalgesic and/or inflammatory conditions in which C-fibers play a pathophysiological role by eliciting neurogenic pain or inflammation.

L5 ANSWER 13 OF 80 USPATFULL

AN 1999:61253 USPATFULL

TI Peptide derivatives

IN Stein, Mark Morris, Wilmington, DE, United States

Trainor, Diane Amy, Glen Mills, PA, United States

PA Zeneca Inc., Wilmington, DE, United States (U.S. corporation)

PI US 5907068 19990525

AI US 1992-941001 19920904 (7)

RLI Division of Ser. No. US 1990-491757, filed on 9 Mar 1990, now patented, Pat. No. US 5194588 which is a division of Ser. No. US 1987-5538, filed on 20 Jan 1987, now patented, Pat. No. US 4910190 which is a continuation-in-part of Ser. No. US 1986-821150, filed on 21 Jan 1986, now abandoned

PRAI GB 1985-1522 19850122

GB 1985-1523 19850122

GB 1985-1524 19850122

DT Utility

EXNAM Primary Examiner: Tsang, Cecilia J.; Assistant Examiner: Marshall, S. G.

CLMN Number of Claims: 2

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 5465

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention concerns pharmaceutically useful trifluoromethyl ketone substituted di-, tri- and tetra-peptide derivatives of the formulae Ia, Ib, Ic set out hereinafter, and salts thereof which are inhibitors of human leukocyte elastase. Also described herein are pharmaceutical compositions containing a peptide derivative and processes and intermediates for use in the manufacture of the peptide derivatives.

L5 ANSWER 14 OF 80 USPATFULL

AN 1999:22097 USPATFULL

TI Morpholine and thiomorpholine tachykinin receptor antagonists

IN Dom, Conrad P., Plainfield, NJ, United States

PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

PI US 5872116 19990216

AI US 1997-959393 19971028 (8)

RLI Division of Ser. No. US 1995-525259, filed on 8 Sep 1995, now patented, Pat. No. US 5719147 And a continuation-in-part of Ser. No. US 1993-169889, filed on 17 Dec 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-61914, filed on 19 May 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-971448, filed on 4 Nov 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-905976, filed on 29 Jun 1992, now abandoned

DT Utility

EXNAM Primary Examiner: Weddington, Kevin E.

LREP Thies, J. Eric; Rose, David L.

CLMN Number of Claims: 21

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 8249

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Substituted heterocycles of the general structural formula: ##STR1## are tachykinin receptor antagonists useful in the treatment of inflammatory diseases, pain or migraine, asthma and emesis, and calcium channel blockers useful in the treatment of cardiovascular conditions such as angina, hypertension or ischemia.

L5 ANSWER 15 OF 80 USPATFULL

AN 1999:12924 USPATFULL

TI Substituted 4-arylbutyric acid derivatives as matrix metalloprotease

IN Kluender, Harold C. E., Trumbull, CT, United States

Dixon, Brian R., Woodbridge, CT, United States

Brittelli, David R., Branford, CT, United States

PA Bayer Corporation, Pittsburgh, PA, United States (U.S. corporation)

PI US 5863915 19990126

AI US 1997-857004 19970515 (8)

PRAI US 1996-51008 19960515 (60)

DT Utility

EXNAM Primary Examiner: Shah, Mukund J.; Assistant Examiner: Rao, Deepak R.

CLMN Number of Claims: 13

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 1430

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Inhibitors for matrix metalloproteases, pharmaceutical compositions containing them, and a process for using them to treat a variety of physiological conditions. The compounds of the invention have the generalized formula ##STR1## wherein R.sub.1 represents C.sub.6-C.sub.12 alkyl; C.sub.5-C.sub.12 alkoxy; C.sub.5-C.sub.12 alkylthio; a polyether of formula R.sub.2 O(C.sub.2 H.sub.4 O).sub.a -- in which a is 1 or 2 and R.sub.2 is C.sub.1-C.sub.5 alkyl, phenyl, or benzyl; and substituted alkynyl of formula R.sub.3 (CH.sub.2).sub.b --C.tbd.C--; in which b is 1-10 and R.sub.3 is H--, HO--, or R.sub.4 O-- in which R.sub.4 is C.sub.1-C.sub.3 alkyl, phenyl, or benzyl. The alkyl, phenyl, and benzyl portions of R.sub.1 may bear at least one pharmaceutically-acceptable substituent. The subscript n is 2-4. R.sub.5 represents phenyl; imidoyl of 4-12 carbon atoms; (3H)-benzo-1,2,3-triazin-4-on-3-yl; N-saccharinyl; (2H)-phthalazin-1-on-2-yl; 2-benzoxazolin-2-on-3-yl; 5,5-dimethylloxazolidine-2,4-dion-3-yl; and thiazolidine-2,4-dion-3-yl; with the phenyl and benzo portions of R.sub.5 permissibly bearing at least one pharmaceutically-acceptable substituent. Pharmaceutically acceptable salts of these materials are also included.

L5 ANSWER 16 OF 80 USPATFULL

AN 1998:162483 USPATFULL

TI Sialyl Le.sup.x analogues as inhibitors of cellular adhesion

IN DeFrees, Shawn A., San Marcos, CA, United States

PA Cytel Corporation, San Diego, CA, United States (U.S. corporation)

PI US 5854218 19981229

AI US 1996-730553 19961015 (8)

RLI Continuation-in-part of Ser. No. US 1995-485453, filed on 7 Jun 1995 which is a continuation-in-part of Ser. No. US 1994-345072, filed on 28 Nov 1994, now patented, Pat. No. US 5604207 which is a continuation-in-part of Ser. No. US 1994-241645, filed on 12 May 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-62120, filed on 14 May 1993, now abandoned

PRAI US 1995-5545 19951018 (60)

DT Utility

EXNAM Primary Examiner: Fonda, Kathleen K.

LREP Townsend and Townsend and Crew LLP

CLMN Number of Claims: 5

ECL Exemplary Claim: 1

DRWN 23 Drawing Figure(s); 23 Drawing Page(s)

LN.CNT 4217

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to analogues of sialyl Le.sup.x that inhibit cellular adhesion between a selectin and cells that express sialyl Le.sup.x on their surfaces, as well as methods and compositions using the same, intermediates and methods for the preparation of the cellular adhesion inhibitor compounds and their intermediates. A contemplated intermediate or inhibitor compound has a structure that corresponds to that of Formula A, ##STR1##

L5 ANSWER 17 OF 80 USPATFULL

AN 1998:156821 USPATFULL

TI Composition containing peptides and nucleic acids and methods of making same

IN Kochel, Bonawentura, Wroclaw, Poland

PA Immune Modulation Maximum, New York, NY, United States (U.S. corporation)

PI US 5849196 19981215

AI US 1996-726650 19961007 (8)

DT Utility

EXNAM Primary Examiner: Elliott, George C.; Assistant Examiner: Larson, Thomas G.LREP Carrier, Blackman & Associates, P.C.; Carrier, Joseph P.; Esser, William F.

CLMN Number of Claims: 16

ECL Exemplary Claim: 9

DRWN 6 Drawing Figure(s); 3 Drawing Page(s)

LN.CNT 946

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An improved composition containing peptides and nucleic acids has active components, i.e., which heighten the phagocytic activity of neutrophils, consisting of molecules with a molecular weight of at least 8 kDa, and preferably at least 15 kDa. The active components comprise peptides without aromatic portions and will absorb light at an absorption band of .DELTA.lamda.=200-235 nm, .lamda.sub.max=205 nm, in the UV spectrum. The composition is nontoxic and is formulated using casein, blood albumin, beef peptone, nucleic acid (RNA) and a base such as sodium hydroxide. The composition stimulates phagocytic activity of neutrophils if used at sufficient concentrations. A separate composition is obtained using the same components of manufacture, but filtering or centrifuging the composition to a molecular weight of <8-15 kDa which inhibits phagocytic activity of neutrophils for application in treating auto immune diseases.

L5 ANSWER 18 OF 80 USPATFULL

AN 1998:154280 USPATFULL

TI Methods of treating pulmonary hypertension

IN Gehlert, Donald Richard, Indianapolis, IN, United States

Steinberg, Mitchell Irvin, Indianapolis, IN, United States

PA Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)

PI US 5846973 19981208

AI US 1997-862709 19970523 (8)

PRAI US 1996-18266 19960524 (60)

DT Utility

EXNAM Primary Examiner: Jordan, Kimberly

LREP Gaylo, Paul J.; Boone, David E.

CLMN Number of Claims: 2

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 942

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention provides methods of inhibiting pulmonary hypertensive disease which comprise administering to a mammal in need thereof a compound having activity as a tachykinin receptor antagonist.

L5 ANSWER 19 OF 80 USPATFULL

AN 1998:147415 USPATFULL

TI Inhibitors of collagenase-1 and stromelysin-I metalloproteases, pharmaceutical compositions comprising same and methods of their use

IN Campbell, David A., San Mateo, CA, United States

Patel, Dinesh V., Fremont, CA, United States

Xiao, Xiao-Yi, San Diego, CA, United States

PA Affymax Technologies N.V., Greenford, England (non-U.S. corporation)

PI US 5840698 19981124

AI US 1995-549346 19951027 (8)

RLI Continuation-in-part of Ser. No. US 1995-482211, filed on 7 Jun 1995, now abandoned which is a continuation-in-part of Ser. No. US 1994-329420, filed on 27 Oct 1994, now abandoned

DT Utility

EXNAM Primary Examiner: Achutamurthy, Ponnathapura; Assistant Examiner: Ponnaluri, P.

LREP Swiss, Gerald F.; Stevens, Lauren L.

CLMN Number of Claims: 14

ECL Exemplary Claim: 1

DRWN 17 Drawing Figure(s); 13 Drawing Page(s)

LN.CNT 2250

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are novel inhibitors of collagenase-1 and stromelysin-I metalloproteases. The disclosed inhibitors are mercaptoketone and mercaptoalcohol compounds which are useful in pharmaceutical

compositions and methods for treating or controlling disease states or conditions which involve tissue breakdown, for example, arthropathy, dermatological conditions, bone resorption, inflammatory diseases, and tumor invasion and in the promotion of wound healing.

L5 ANSWER 20 OF 80 USPATFULL

AN 1998:135148 USPATFULL

TI Inhibitors of metalloproteases, pharmaceutical compositions comprising same and methods of their use

IN Campbell, David A., San Mateo, CA, United States

Patel, Dinesh V., Fremont, CA, United States

Xiao, Xiao-Yi, San Diego, CA, United States

PA Affymax Technologies N.V., Greenford, England (non-U.S. corporation)

PI US 5831004 19981103

AI US 1995-549345 19951027 (8)

RLI Continuation-in-part of Ser. No. US 1995-484255, filed on 7 Jun 1995, now abandoned which is a continuation-in-part of Ser. No. US 1994-329420, filed on 27 Oct 1994, now abandoned

DT Utility

EXNAM Primary Examiner: Tsang, Cecilia J.; Assistant Examiner: Delacroix-Muirheid, C.

LREP Swiss, Gerald F.; Stevens, Lauren L.

CLMN Number of Claims: 8

ECL Exemplary Claim: 1

DRWN 17 Drawing Figure(s); 13 Drawing Page(s)

LN.CNT 2313

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are novel inhibitors of metalloproteases, in particular matrix metalloproteases. The disclosed inhibitors are mercaptoketone and mercaptoalcohol compounds which are useful in pharmaceutical compositions and methods for treating or controlling disease states or conditions which involve tissue breakdown, for example, arthropathy, dermatological conditions, bone resorption, inflammatory diseases, and tumor invasion and in the promotion of wound healing.

L5 ANSWER 21 OF 80 USPATFULL

AN 1998:124684 USPATFULL

TI Antineoplastic use and pharmaceutical compositions containing them

IN Wicnienski, Nancy A., Kalamazoo, MI, United States

Kelly, Robert C., Augusta, MI, United States

Wuts, Peter G. M., Kalamazoo, MI, United States

PA Pharmacia & Upjohn Company, Kalamazoo, MI, United States (U.S. corporation)

PI US 5821363 19981013

WO 9520582 19950803

AI US 1996-676370 19960723 (8)

WO 1995-US551 19950126

19960723 PCT 371 date

19960723 PCT 102(e) date

RLI Continuation-in-part of Ser. No. US 1994-189235, filed on 28 Jan 1994, now abandoned

DT Utility

EXNAM Primary Examiner: Trinh, Ba K.

LREP Jameson, William G.

CLMN Number of Claims: 23

ECL Exemplary Claim: 1,20,22

DRWN No Drawings

LN.CNT 7196

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention provides 7-deoxy-DELTA.sup.12,13 -iso-taxol of formula (I) which are useful for the treatment of the same cancers for which taxol has been shown active. ##STR1##

L5 ANSWER 22 OF 80 USPATFULL

AN 1998:115719 USPATFULL

TI Sialyl Le.sup.x analogues as inhibitors of cellular adhesion

IN De Frees, Shawn, San Marcos, CA, United States

Gaeta, Federico C. A., Foster City, CA, United States

Gaudino, John J., Westlake Village, CA, United States

Zheng, Zhongli, Lexington, MA, United States

Hayashi, Masaji, Kobe, Japan

PA Cytel Corporation, San Diego, CA, United States (U.S. corporation)

PI US 5811404 19980922

AI US 4854535 19950607 (8)

RLI Continuation-in-part of Ser. No. 345072, filed on 28 Nov 1994, now patented, Pat. No. 5604207 which is a continuation-in-part of Ser. No. 241645, filed on 12 May 1994 which is a continuation-in-part of Ser. No. 62120, filed on 14 May 1993, now abandoned

DT Utility

EXNAM Primary Examiner: Fonda, Kathleen K.

LREP Townsend and Townsend and Crew

CLMN Number of Claims: 5

ECL Exemplary Claim: 4

DRWN No Drawings

LN.CNT 2846

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to analogues of sialyl Le.sup.x the inhibit cellular adhesion between a selectin and cell that express sialyl Le.sup.x on their surfaces, as well as methods and compositions using the same, intermediates and methods for the preparation of the cellular adhesion inhibitor compounds and their intermediates. A contemplated intermediate or inhibitor compound has a structure that corresponds to that of Formula A, ##STR1## wherein: Z is selected from the group consisting of hydrogen, C.sub.1 -C.sub.6 acyl and ##STR2##

L5 ANSWER 23 OF 80 USPATFULL

AN 1998:111961 USPATFULL

TI Method for selectively reducing activated leukocyte cell population

IN Leong, Simon, Vancouver, Canada

PA Quadra Logic Technologies, Inc., Vancouver, Canada (non-U.S. corporation)

University of British Columbia, Vancouver, Canada (non-U.S. corporation)

PI US 5807881 19980915

AI US 1994-309509 19940922 (8)

RLI Continuation-in-part of Ser. No. US 1992-889707, filed on 27 May 1992

DT Utility

EXNAM Primary Examiner: Burn, Brian M.

LREP Morrison & Foerster

CLMN Number of Claims: 19

ECL Exemplary Claim: 1

DRWN 21 Drawing Figure(s); 9 Drawing Page(s)

LN.CNT 1016

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Multiple sclerosis and rheumatoid arthritis can be treated effectively using photodynamic therapy. In this protocol, a photoactive compound is administered, allowed to distribute in the effected subject, and the subject is then irradiated to activate the photoactive compound. Alternatively, the blood of a subject to be treated can be subjected to PDT extracorporeally. In the case of rheumatoid arthritis, localized treatment at the joints may also be employed.

L5 ANSWER 24 OF 80 USPATFULL

AN 1998:82754 USPATFULL

TI Morpholine compounds are prodrugs useful as tachykinin receptor antagonists

IN Dorn, Conrad P., Plainfield, NJ, United States

PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

PI US 5780467 19980714

AI US 1997-907738 19970808 (8)

RLI Division of Ser. No. US 1995-525870, filed on 8 Sep 1995, now patented, Pat. No. US 5691336 which is a continuation-in-part of Ser. No. US 1994-206771, filed on 4 Mar 1994, now abandoned

DT Utility

EXNAM Primary Examiner: Higel, Floyd D.

LREP Thies, J. Eric; Rose, David L.

CLMN Number of Claims: 19

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 7260

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Substituted heterocycles of the general structural formula: ##STR1## are tachykinin receptor antagonists useful in the treatment of inflammatory diseases, pain or migraine, asthma, and emesis.

L5 ANSWER 25 OF 80 USPATFULL

AN 1998:79203 USPATFULL

TI Selective cell inactivation in blood

IN North, Janice, Vancouver, Canada

PA University of British Columbia, Vancouver, Canada (non-U.S. corporation)

Quadra Logic Technologies Inc., Vancouver, Canada (non-U.S. corporation)

PI US 5776966 19980707

AI US 1992-889707 19920527 (7)

DT Utility

EXNAM Primary Examiner: Raymond, Richard L.; Assistant Examiner: Burn, Brian

M.

LREP Morrison & Foerster

CLMN Number of Claims: 12

ECL Exemplary Claim: 1

DRWN 17 Drawing Figure(s); 5 Drawing Page(s)

LN.CNT 599

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Treatment with a set of porphyrin compounds using a photodynamic therapy approach is able selectively to lower elevated levels of activated leukocytes in a leukocyte population. This is particularly helpful in subjects containing such elevated levels of T-cell subsets, such as HIV-infected subjects.

L5 ANSWER 26 OF 80 USPATFULL

AN 1998:54921 USPATFULL

TI Heterocyclic compounds

IN Hohlweg, Rolf, Kvistgaard, Denmark

PA Novo Nordisk A/S, Bagsvaerd, Denmark (non-U.S. corporation)

PI US 5753678 19980519

AI US 1996-715665 19960918 (8)

PRAI DK 1995-1040 19950919

DK 1995-1041 19950919

DT Utility

EXNAM Primary Examiner: Ivy, C. Warren; Assistant Examiner: Aulakh, Charanjit S.

LREP Zelson, Steve T.; Lambiris, Elias J.

CLMN Number of Claims: 17

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 934

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel N-substituted amino alcohols, amino acids and acid derivatives thereof in which a substituted alkyl chain forms part of the N-substituent or salts thereof, to methods for their preparation, to compositions containing them, and to their use for the clinical treatment of painful, hyperalgesic and/or inflammatory conditions in which C-fibers play a pathophysiological role by eliciting neurogenic pain or inflammation.

L5 ANSWER 27 OF 80 USPATFULL

AN 1998:51585 USPATFULL

TI Sialic acid/fucose based medicaments

IN Dasgupta, Falguni, Alameda, CA, United States

Musser, John Henry, San Carlos, CA, United States

PA Glycomed Incorporated, Alameda, CA, United States (U.S. corporation)

PI US 5750508 19980512

AI US 1993-78949 19930616 (8)

DT Utility

EXNAM Primary Examiner: Fonda, Kathleen K.

LREP Lyon & Lyon

CLMN Number of Claims: 20

ECL Exemplary Claim: 1

DRWN 8 Drawing Figure(s); 6 Drawing Page(s)

LN.CNT 1254

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds that are synthetically inexpensive to make relative to the naturally occurring selectin ligands and that retain selectin binding activity are described that have a three-dimensionally stable configuration for sialic acid and fucose, or analogs or derivatives of these groups, such that sialic acid and fucose are separated by a non-carbohydrate linker that permits binding between those groups and the selectins, such compounds being represented by the following general structure formula I(a): ##STR1## wherein m and n are independently an integer of from 1 to 5, Y and Z are independently a connecting moiety selected from the group consisting of --CH.sub.2 --, --O--, --S--, --NR' and --NR'R''--(wherein R' and R'' are independently H or an alkyl containing 1 to 4 carbon atoms); X is a connecting moiety which is selected from the group consisting of --O--, --S-- and --N--; and --R" may be --R" or any moiety which does not interfere with the three-dimensional configuration of A or B so as to interfere with selectin binding and is preferably a moiety selected from the group consisting of --OR", --SR", --I, --N.sub.3, and --NR'R'', and A is selected from the group consisting of .alpha. and .beta. forms of sialic acid, Kemp's acid, Quinic acid, Glyceric acid, Lactic acid and acetic acid, and esters thereof and B is selected from the group consisting of .alpha. and .beta. forms of L-Fucose and esters and substituted forms thereof wherein one or more of the --OH groups is independently --F, or --NR.sub.4, R.sub.5 wherein R.sub.4 and R.sub.5 are independently an

alkyl contain 1 to 5 carbons.

L5 ANSWER 28 OF 80 USPATFULL

AN 1998:42474 USPATFULL

TI 1-substituted, 2-substituted 1H-imidazo[4,5-C]quinolin-4-amines

IN Gerster, John F., Woodbury, MN, United States

Crooks, Stephen L., Mahtomedi, MN, United States

Lindstrom, Kyle J., Houlton, WI, United States

PA Minnesota Mining and Manufacturing Company, St. Paul, MN, United States (U.S. corporation)

PI US 5741909 19980421

AI US 1997-789264 19970128 (8)

RLI Division of Ser. No. US 1994-353802, filed on 12 Dec 1994, now patented, Pat. No. US 5605899 which is a division of Ser. No. US 1992-938295, filed on 28 Aug 1992, now patented, Pat. No. US 5389640 which is a continuation-in-part of Ser. No. US 1992-838475, filed on 19 Feb 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-687326, filed on 18 Apr 1991, now abandoned which is a continuation-in-part of Ser. No. US 1991-662926, filed on 1 Mar 1991, now abandoned

DT Utility

EXNAM Primary Examiner: Rotman, Alan L.

LREP Howard, MarySusan; Ringsred, Ted K.; Kirn, Walter N.

CLMN Number of Claims: 2

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 2448

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB 1-substituted, 2-substituted 1H-imidazo[4,5-c]-quinolin-4-amines are disclosed. These compounds function as antiviral agents, they induce biosynthesis of interferon, and they inhibit tumor formation in animal models. This invention also provides intermediates for preparing such compounds, pharmaceutical compositions containing such compounds, and pharmacological methods of using such compounds.

L5 ANSWER 29 OF 80 USPATFULL

AN 1998:25212 USPATFULL

TI Peptide derivatives

IN Edwards, Philip Duke, Claymont, DE, United States

Schwartz, John Anthony, Wilmington, DE, United States

Stein, Mark Morris, Wilmington, DE, United States

Trainor, Diane Amy, Glen Mills, PA, United States

Wildonger, Richard Alan, Newark, DE, United States

PA Zeneca Inc., Wilmington, DE, United States (U.S. corporation)

PI US 5726158 19980310

AI US 1995-467333 19950606 (8)

RLI Continuation of Ser. No. US 1990-482617, filed on 21 Feb 1990, now abandoned which is a division of Ser. No. US 1987-5538, filed on 20 Jan 1987, now patented, Pat. No. US 4910190 which is a continuation-in-part of Ser. No. US 1986-821150, filed on 21 Jan 1986, now abandoned

PRAI GB 1985-1522 19850122

GB 1985-1523 19850122

GB 1985-1524 19850122

DT Utility

EXNAM Primary Examiner: Johnson, Jerry D.

LREP Hohenschutz, Liza D.

CLMN Number of Claims: 12

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 5961

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention concerns pharmaceutically useful trifluoromethyl ketone substituted di-, tri- and tetra-peptide derivatives of the formulae Ia, Ib, Ic set out hereinafter, and salts thereof, which are inhibitors of human leukocyte elastase. Also described herein are pharmaceutical compositions containing a peptide derivative and processes and intermediates for use in the manufacture of the peptide derivatives.

L5 ANSWER 30 OF 80 USPATFULL

AN 1998:19825 USPATFULL

TI Process for preparing substituted polyazamacrocycles

IN Lennon, Patrick J., Clayton, MO, United States

Henke, Susan L., Webster Grove, MO, United States

Aston, Karl W., Pacific, MO, United States

PA The Monsanto Company, St. Louis, MO, United States (U.S. corporation)

PI US 5721361 19980224

AI US 1996-665070 19960611 (8)

RLI Continuation of Ser. No. US 1995-486434, filed on 7 Jun 1995, now

abandoned
DT Utility
EXNAM Primary Examiner: Shah, Mukund J.; Assistant Examiner: Sripada, Pavanaram K.
LREP Roth, Michael J.; Williams, Roger A.
CLMN Number of Claims: 24
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2348
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A process for preparing a substituted polyazamacrocyclic compound which comprises contacting a diamine or triamine and a dicarboxylic acid or ester or anhydride thereof in the presence of a suitable base and a suitable solvent to produce the substituted polyazamacrocyclic compound that when an ester of said dicarboxylic acid is used, said suitable base is optional, and when said dicarboxylic acid or an anhydride of said dicarboxylic acid is used, the reaction mixture further comprises a suitable coupling agent.

L5 ANSWER 31 OF 80 USPATFULL
AN 1998:17310 USPATFULL
TI Morpholine and thiomorpholine tachykinin receptor antagonists
IN Dorn, Conrad P., Plainfield, NJ, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 5719147 19980217
AI US 1995-525259 19950908 (8)
RLI Continuation-in-part of Ser. No. US 1993-169889, filed on 17 Dec 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-61914, filed on 19 May 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-971448, filed on 4 Nov 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-905976, filed on 29 Jun 1992, now abandoned
DT Utility
EXNAM Primary Examiner: Grumbling, Matthew V.
LREP Thies, J. Eric; Rose, David L.
CLMN Number of Claims: 27
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 8352
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Substituted heterocycles of the general structural formula: ##STR1## are tachykinin receptor antagonists useful in the treatment of inflammatory diseases, pain or migraine, asthma and emesis, and calcium channel blockers useful in the treatment of cardiovascular conditions such as angina, hypertension or ischemia.

L5 ANSWER 32 OF 80 USPATFULL
AN 1998:14789 USPATFULL
TI Treatment of migraine with morpholine tachykinin receptor antagonists
IN Dorn, Conrad P., Plainfield, NJ, United States
MacCoss, Malcolm, Freehold, NJ, United States
Hale, Jeffrey J., Westfield, NJ, United States
Mills, Sander G., Woodbridge, NJ, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 5716942 19980210
AI US 1995-450198 19950525 (8)
RLI Division of Ser. No. US 1994-206771, filed on 4 Mar 1994, now abandoned
DT Utility
EXNAM Primary Examiner: Jarvis, William R. A.
LREP Thies, J. Eric; Rose, David L.
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 6755
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Substituted heterocycles of the general structural formula: ##STR1## are tachykinin receptor antagonists useful in the treatment of inflammatory diseases, pain or migraine, asthma, emesis and nausea.

L5 ANSWER 33 OF 80 USPATFULL
AN 1998:12025 USPATFULL
TI .alpha.-(1,3-dicarbonylenol ether) methyl ketones as cysteine protease inhibitors
IN Zimmerman, Mary P., Pleasonton, CA, United States
Smith, Robert E., Livermore, CA, United States
Becker, Mark, Walnut Creek, CA, United States
PA Prototek, Inc., Dublin, CA, United States (U.S. corporation)
PI US 5714484 19980203

AI US 1995-481808 19950607 (8)
RLI Continuation-in-part of Ser. No. US 1993-164031, filed on 8 Dec 1993, now patented, Pat. No. US 5486623
DT Utility
EXNAM Primary Examiner: Shah, Mukund J.; Assistant Examiner: Ngo, Tamthom T.
LREP Woodard, Emhardt, Naughton, Moriarty & McNett
CLMN Number of Claims: 3
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1647
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Cysteine protease inhibitors which deactivate the protease by covalently bonding to the cysteine protease and releasing the enolate of a 1,3-dicarbonyl (or its enolic form). The cysteine protease inhibitors of the present invention accordingly comprise a first portion which targets a desired cysteine protease and positions the inhibitor near the thiolate anion portion of the active site of the protease, and a second portion which covalently bonds to the cysteine protease and irreversibly deactivates that protease by providing a carbonyl or carbonyl-equivalent which is attacked by the thiolate anion of the active site of the cysteine protease to sequentially cleave a .beta.-dicarbonyl enol ether leaving group.

L5 ANSWER 34 OF 80 USPATFULL
AN 1998:4236 USPATFULL
TI Receptors for fibroblast growth factors
IN Williams, Lewis T., San Francisco, CA, United States
Johnson, Daniel E., San Francisco, CA, United States
Lee, Pauline E., San Diego, CA, United States
PA The Regents of the University of CA, Alameda, CA, United States (U.S. corporation)
PI US 5707632 19980113
AI US 1995-458938 19950602 (8)
RLI Continuation of Ser. No. US 1992-834311, filed on 13 Feb 1992 which is a continuation-in-part of Ser. No. US 1989-377003, filed on 6 Jul 1989, now abandoned
DT Utility
EXNAM Primary Examiner: Chan, Christina Y.; Assistant Examiner: Nolan, Patrick T.
LREP Townsend and Townsend and Crew LLP
CLMN Number of Claims: 14
ECL Exemplary Claim: 1
DRWN 25 Drawing Figure(s); 17 Drawing Page(s)
LN.CNT 2178
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A fibroblast growth factor (FGF) receptor including a basic fibroblast growth factor receptor has been purified. Various forms have been identified including soluble forms lacking any transmembrane segment. DNA sequences encoding full-length fibroblast growth factor receptors and polypeptides comprising a portion of an FGF-R ligand-binding domain have been isolated and sequenced. These DNAs include DNAs encoding for a basic FGF-R and a human FGF-R and are operably linked to control sequences and expressed in a culture of a compatible host transformed, transfected or electroporesed by a cloning vehicle containing the DNA sequence. The invention also comprises antibodies to the receptor, methods of synthesizing the growth factor receptor proteins, methods for providing analogs of the fibroblast growth factor receptors. Methods for evaluating compositions which promote or inhibit fibroblastic growth factors and compositions which are agonistic or antagonistic to fibroblast growth factor receptors are also provided. Diagnostic and therapeutic uses are described.

L5 ANSWER 35 OF 80 USPATFULL
AN 97:112623 USPATFULL
TI Phosphonate nucleoside analogs
IN Kim, Choung Un, Madison, CT, United States
Martin, John C., San Carlos, CA, United States
Luh, Bing Uh, Killingworth, CT, United States
Misco, Peter F., Durham, CT, United States
PA Institute of Organic Chemistry and Biochemistry of the Academy of Sciences of the Czech Republic, Czech Republic (non-U.S. corporation)
Rega Stichting v.z.w., Belgium (non-U.S. corporation)
PI US 5693798 19971202
AI US 1995-488337 19950607 (8)
RLI Division of Ser. No. US 1995-391312, filed on 17 Feb 1995 which is a continuation of Ser. No. US 1991-765774, filed on 26 Sep 1991, now abandoned which is a continuation-in-part of Ser. No. US 1990-481569,

filed on 22 Feb 1990, now abandoned which is a continuation-in-part of Ser. No. US 1989-352303, filed on 15 May 1989, now abandoned

DT Utility

EXNAM Primary Examiner: Berch, Mark L.

LREP Hensley, Max D.

CLMN Number of Claims: 4

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 2641

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Provided are compounds of the following formulae:

A phosphonomethoxymethoxymethyl purine/pyrimidine derivative of the formula ##STR1## wherein X and X' are the same or different and are hydrogen or alkyl. R and R' are the same or different and are hydrogen, alkyl, hydroxyalkyl or alkanoyl and

B is a purine or pyrimidine base.

A 4'-phosphonomethoxytetrahydrofuran-1'-purine-pyrimidine of the formula ##STR2## wherein X and X' are the same or different and are hydrogen or alkyl, Y and Z are the same or different and are hydrogen, hydroxyl or alkyl or Y+Z is an alkenyl, an epoxide or cyclopropyl, and

B is a purine or pyrimidine base.

L5 ANSWER 36 OF 80 USPATFULL

AN 97:109895 USPATFULL

TI Morpholine compounds are prodrugs useful as tachykinin receptor antagonists

IN Dorn, Conrad P., Plainfield, NJ, United States

Hale, Jeffrey J., Westfield, NJ, United States

Maccoss, Malcolm, Freehold, NJ, United States

Mills, Sander G., Woodbridge, NJ, United States

PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

PI US 5691336 19971125

AI US 1995-525870 19950908 (8)

RLI Continuation-in-part of Ser. No. US 1994-206771, filed on 4 Mar 1994, now abandoned

DT Utility

EXNAM Primary Examiner: Higell, Floyd D.

LREP Thies, J. Eric; Rose, David L.

CLMN Number of Claims: 25

ECL Exemplary Claim: 1,24

DRWN No Drawings

LN.CNT 7292

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Substituted heterocycles of the general structural formula: ##STR1## are tachykinin receptor antagonists useful in the treatment of inflammatory diseases, pain or migraine, asthma, and emesis.

L5 ANSWER 37 OF 80 USPATFULL

AN 97:104632 USPATFULL

TI Nucleoside analogs

IN Kim, Choung Un, Madison, CT, United States

Martin, John C., San Carlos, CA, United States

Luh, Bing Uh, Killingworth, CT, United States

Misco, Peter F., Durham, CT, United States

PA Institute of Organic Chemistry and Biochemistry of the Academy of Sciences of the Czech Republic, Czech Republic (non-U.S. government) Rega Stichting v.z.w., Belgium (non-U.S. corporation)

PI US 5686611 19971111

AI US 1995-488339 19950607 (8)

RLI Division of Ser. No. US 1995-391312, filed on 17 Feb 1995 which is a continuation of Ser. No. US 1991-765774, filed on 26 Sep 1991, now abandoned which is a continuation-in-part of Ser. No. US 1990-481569, filed on 22 Feb 1990, now abandoned which is a continuation-in-part of Ser. No. US 1989-352303, filed on 15 May 1989, now abandoned

DT Utility

EXNAM Primary Examiner: Berch, Mark L.

LREP Hensley, Max D.

CLMN Number of Claims: 5

ECL Exemplary Claim: 1,2

DRWN No Drawings

LN.CNT 2646

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Provided are compounds of the following formulae: A phosphonomethoxymethoxymethyl purine/pyrimidine derivative of the

formula ##STR1## wherein X and X' are the same or different and are hydrogen or alkyl. R and R' are the same or different and are hydrogen, alkyl, hydroxyalkyl or alkanoyl and

B is a purine or pyrimidine base.

A compound of formula (VI) ##STR2## wherein X is halogen, Y is S-phenyl, Se-phenyl or halogen and B is hypoxanthine, xanthine, guanine, 8-bromoguanine, 8-chloroguanine, 8-methylguanine, 8-thioguanine, 3-deazaguanine, purine, 2-aminopurine, 2,6-diaminopurine, adenine, 3-deazaadenine, 8-aminoguanine, 8-hydrazinoguanine, 8-hydroxyguanine, cytosine, 5-ethylcytosine, 5-methylcytosine, thymine, uracil, 5-chlorouracil, 5-bromouracil, 5-ethyluracil, 5-iodouracil, 5-propyluracil or 5-vinyluracil, 2-acetamido-6-diphenylcarbamoyl-purine, 6-N-dimethylamino-methyladenine or 6-N-pivaloyl-adenine.

A compound of formula (VII) ##STR3## wherein B is guanine, 8-guanine, 8-bromoguanine, 8-chloroguanine, 8-methylguanine, 8-thioguanine, 3-deazaguanine, 8-aminoguanine, 8-hydrazinoguanine, 8-hydroxyguanine, cytosine, 5-ethylcytosine, or 5-methylcytosine.

L5 ANSWER 38 OF 80 USPATFULL

AN 97:96530 USPATFULL

TI Sialic acid/fucose based medicaments

IN Dasgupta, Falguni, Alameda, CA, United States

Musser, John Henry, San Carlos, CA, United States

PA Glycomed Incorporated, Alameda, CA, United States (U.S. corporation)

PI US 5679321 19971021

AI US 1995-468788 19950606 (8)

RLI Division of Ser. No. US 1993-78948, filed on 17 Jun 1993, now abandoned

DT Utility

EXNAM Primary Examiner: Hutzell, Paula K.; Assistant Examiner: Minnifield, N. M.

LREP Lyon & Lyon LLP

CLMN Number of Claims: 11

ECL Exemplary Claim: 1

DRWN 7 Drawing Figure(s); 7 Drawing Page(s)

LN.CNT 1199

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds that are synthetically inexpensive to make relative to the naturally occurring selectin ligands and that retain selectin binding activity are described that have a three-dimensionally stable configuration for sialic acid and fucose, or analogs or derivatives of these groups, such that sialic acid and fucose are separated by a non-carbohydrate linker that permits binding between those groups and the selectins, such compounds being represented by the following general structural formula I(a): ##STR1## wherein m and n are independently an integer of from 1 to 5, Y and Z are independently a connecting moiety selected from the group consisting of --CH₂sub.2 --, --O--, --S--, --NR' and --NR'R''-- (wherein R' and R'' are independently H or an alkyl containing 1 to 4 carbon atoms); X is a connecting moiety which is selected from the group consisting of --O--, --S-- and --N--; and --R'' may be --R'' or any moiety which does not interfere with the three-dimensional configuration of A or B so as to interfere with selectin binding and is preferably a moiety selected from the group consisting of --OR'', --SR'', --I, --N.sub.3, and --NR'R'', and A is selected from the group consisting of .alpha. and .beta. forms of sialic acid, Kemp's acid, Quinic acid, Glyceric acid, Lactic acid and acetic acid, and esters thereof and B is selected from the group consisting of .alpha. and .beta. forms of L-Fucose and esters and substituted forms thereof wherein one or more of the --OH groups is independently --F, or --NR.sub.IV, R.sub.V wherein R.sub.IV and R.sub.V are independently an alkyl contain 1 to 5 carbons.

L5 ANSWER 39 OF 80 USPATFULL

AN 97:75978 USPATFULL

TI Sialic acid/fucose based assay reagents and assay methods

IN Dasgupta, Falguni, Alameda, CA, United States

Musser, John Henry, San Carlos, CA, United States

PA Glycomed Incorporated, Alameda, CA, United States (U.S. corporation)

PI US 5660992 19970826

AI US 1995-464507 19950605 (8)

RLI Division of Ser. No. US 1993-78949, filed on 16 Jun 1993, now abandoned

DT Utility

EXNAM Primary Examiner: Hutzell, Paula K.; Assistant Examiner: Minnifield, N. M.

LREP Lyon & Lyon LLP

CLMN Number of Claims: 20

ECL Exemplary Claim: 1

DRWN 8 Drawing Figure(s); 6 Drawing Page(s)

LN.CNT 1262

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds that are synthetically inexpensive to make relative to the naturally occurring selectin ligands and that retain selectin binding activity are described that have a three-dimensionally stable configuration for sialic acid and fucose, or analogs or derivatives of these groups, such that sialic acid and fucose are separated by a non-carbohydrate linker that permits binding between those groups and the selectins, such compounds being represented by the following general structural formula I(a): ##STR1## wherein m and n are independently an integer of from 1 to 5, Y and Z are independently a connecting moiety selected from the group consisting of --CH.sub.2 --, --O--, --S--, --NR' and --NR'R-- (wherein R' and R" are independently H or an alkyl containing 1 to 4 carbon atoms); X is a connecting moiety which is selected from the group consisting of --O--, --S-- and --N--; and --R" may be --R" or any moiety which does not interfere with the three-dimensional configuration of A or B so as to interfere with selectin binding and is preferably a moiety selected from the group consisting of --OR", --SR", --I, --N.sub.3, and --NR'R" and A is selected from the group consisting of .alpha. and .beta. forms of sialic acid, Kemp's acid, Quinic acid, Glyceric acid, Lactic acid and acetic acid, and esters thereof and B is selected from the group consisting of .alpha. and .beta. forms of L-Fucose and esters and substituted forms thereof wherein one or more of the --OH groups is independently --F, or --NR.sup.IV, R.sup.V wherein R.sup.IV and R.sup.V are independently an alkyl contain 1 to 5 carbons.

L5 ANSWER 40 OF 80 USPATFULL

AN 97:73587 USPATFULL

TI Sialic acid/fucose based medicaments

IN Dasgupta, Falguni, San Leandro, CA, United States

Musser, John H., San Carlos, CA, United States

Levy, Daniel E., Oakland, CA, United States

Tang, Peng Cho, Moraga, CA, United States

PA Glycomed Incorporated, Alameda, CA, United States (U.S. corporation)

PI US 5658880 19970819

AI US 1994-289715 19940812 (8)

RLI Continuation-in-part of Ser. No. US 1993-78949, filed on 16 Jun 1993, now abandoned

DT Utility

EXNAM Primary Examiner: Kunz, Gary L.; Assistant Examiner: Fonda, Kathleen Kahler

LREP Lyon & Lyon

CLMN Number of Claims: 48

ECL Exemplary Claim: 1

DRWN 8 Drawing Figure(s); 6 Drawing Page(s)

LN.CNT 2200

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds that exhibit selectin binding activity are described and have the following structural formula: ##STR1## where W is selected from a group including structures a-d below ##STR2## wherein p is an integer of from 0-2, q is an integer of from 0-3, and r is an integer of from 0-5; A is selected from the group consisting of .alpha. and .beta. forms of sialic acid, Kemp's acid, quinic acid, R and S forms of mandelic acid, R and S forms of glyceric acid, R and S forms of lactic acid, propionic and acetic acid, and esters and amides thereof, --SO.sub.3, sulfonate, --PO.sub.3, phosphonate, trifluoromethyl, diazine and triazine; is selected from a group consisting of .alpha. and .beta. forms of fucose, arabinose and esters and substituted forms thereof wherein one or more of the OH groups is independently substituted with F, N.sub.3, NHAc, NHCOCF.sub.3. The remaining variable are described in the specification.

L5 ANSWER 41 OF 80 USPATFULL

AN 97:61681 USPATFULL

TI PLA.sub.2 inhibitors

IN Lennon, Patrick James, Clayton, MO, United States

PA Monsanto Company, St. Louis, MO, United States (U.S. corporation)

PI US 5648349 19970715

AI US 1995-430054 19950427 (8)

RLI Division of Ser. No. US 1994-259720, filed on 14 Jun 1994, now patented, Pat. No. US 5434288 which is a continuation-in-part of Ser. No. US 1992-984022, filed on 1 Dec 1992, now abandoned

DT Utility

EXNAM Primary Examiner: Richter, Johann; Assistant Examiner: Ambrose, Michael

G.

LREP Fitzpatrick, Cella, Harper & Scinto

CLMN Number of Claims: 13

ECL Exemplary Claim: 1,13

DRWN No Drawings

LN.CNT 1080

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB PLA.sub.2 inhibitors selected from the group consisting of ##STR1## wherein A is selected from the group consisting of ##STR2## and Z, W, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8, R.sub.9, X, X' and Y are as defined herein.

L5 ANSWER 42 OF 80 USPATFULL

AN 97:49744 USPATFULL

TI Process for preparing morpholine tachykinin receptor antagonists

IN Dom, Conrad P., Plainfield, NJ, United States

PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

PI US 5637699 19970610

AI US 1995-445489 19950522 (8)

RLI Division of Ser. No. US 1993-169889, filed on 17 Dec 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-61914, filed on 19 May 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-971448, filed on 4 Nov 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-905976, filed on 29 Jun 1992, now abandoned

DT Utility

EXNAM Primary Examiner: Grumbling, Matthew V.

LREP Thies, J. Eric; Rose, David L.

CLMN Number of Claims: 2

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 6269

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Substituted heterocycles of the general structural formula: ##STR1## are tachykinin receptor antagonists useful in the treatment of inflammatory diseases, pain or migraine, asthma and emesis, and calcium channel blockers useful in the treatment of cardiovascular conditions such as angina, hypertension or ischemia.

L5 ANSWER 43 OF 80 USPATFULL

AN 97:17918 USPATFULL

TI Compositions and methods for enhanced drug delivery

IN Hale, Ron L., Woodside, CA, United States

Lu, Amy, Los Altos, CA, United States

Solas, Dennis, San Francisco, CA, United States

Selick, Harold E., Belmont, CA, United States

Oldenburg, Kevin R., Fremont, CA, United States

Zaffaroni, Alejandro C., Atherton, CA, United States

PA Affymax Technologies N.V., Middlesex, England (non-U.S. corporation)

PI US 5607691 19970304

AI US 1995-449188 19950524 (8)

RLI Continuation of Ser. No. US 1993-164293, filed on 9 Dec 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-77296, filed on 14 Jun 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-898219, filed on 12 Jun 1992, now abandoned And a continuation-in-part of Ser. No. US 1993-9463, filed on 27 Jan 1993, now abandoned

DT Utility

EXNAM Primary Examiner: Levy, Neil S.

LREP Stevens, Lauren L.

CLMN Number of Claims: 5

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 5349

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to methods of delivering pharmaceutical agents across membranes, including the skin layer or mucosal membranes of a patient. A pharmaceutical agent is covalently bonded to a chemical modifier, via a physiologically cleavable bond, such that the membrane transport and delivery of the agent is enhanced.

L5 ANSWER 44 OF 80 USPATFULL

AN 97:16054 USPATFULL

TI 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines

IN Gerster, John F., Woodbury, MN, United States

Crooks, Stephen L., Mahtomedi, MN, United States

Lindstrom, Kyle J., Houlton, WI, United States

PA Minnesota Mining and Manufacturing Company, St. Paul, MN, United States

(U.S. corporation)
PI US 5605899 19970225
AI US 1994-353802 19941212 (8)
RLI Division of Ser. No. US 1992-938295, filed on 28 Aug 1992, now patented, Pat. No. US 5389640 which is a continuation-in-part of Ser. No. US 1992-838475, filed on 19 Feb 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-687326, filed on 18 Apr 1991, now abandoned which is a continuation-in-part of Ser. No. US 1991-662926, filed on 1 Mar 1991, now abandoned

DT Utility

EXNAM Primary Examiner: Rotman, Alan L.
LREP Griswold, Gary L.; Kim, Walter N.; Ringsred, Ted K.

CLMN Number of Claims: 36

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 2585

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB 1-substituted, 2-substituted 1H-imidazo[4,5-c]-quinolin-4-amines are disclosed. These compounds function as antiviral agents, they induce biosynthesis of interferon, and they inhibit tumor formation in animal models. This invention also provides intermediates for preparing such compounds, pharmaceutical compositions containing such compounds, and pharmacological methods of using such compounds.

L5 ANSWER 45 OF 80 USPATFULL

AN 97:14683 USPATFULL

TI Sialyl Le.sup.x analogues as inhibitors of cellular adhesion

IN DeFrees, Shawn A., San Marcos, CA, United States

Gaeta, Federico C. A., Olivenhain, CA, United States

Gaudino, John J., Westlake Village, CA, United States

Zheng, Zhongli, Lexington, MA, United States

Hayashi, Masaji, Kobe, Japan

PA Cytel Corporation, San Diego, CA, United States (U.S. corporation)

PI US 5604207 19970218

AI US 1994-345072 19941128 (8)

RLI Continuation-in-part of Ser. No. US 1994-241645, filed on 12 May 1994 which is a continuation-in-part of Ser. No. US 1993-62120, filed on 14 May 1993, now abandoned

DT Utility

EXNAM Primary Examiner: Kunz, Gary L.; Assistant Examiner: Fonda, Kathleen Kahler

LREP Townsend and Townsend and Crew

CLMN Number of Claims: 44

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 3352

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The inventive compounds are analogues of sialyl Le.sup.x that inhibit cellular adhesion between a selectin and cells that express sialyl Le.sup.x on their surfaces, and their synthetic intermediates. An inventive compound has structure A, ##STR1## wherein Z is hydrogen, C.sub.1 -C.sub.6 acyl or ##STR2## Y is C(O), SO.sub.2, HNC(O), OC(O) or SC(O); R.sup.1 is an aryl, a substituted aryl or a phenyl C.sub.1 -C.sub.3 alkylene group, wherein an aryl group has one five- or six-membered aromatic ring, a fused five/six-membered aromatic ring, or two fused six-membered aromatic rings, which rings are hydrocarbyl, monooxahydrocarbyl, monothiahydrocarbyl, monoazahydrocarbyl or diazahydrocarbyl rings, and a substituted aryl group is an aryl group having a halo, trifluoromethyl, nitro, C.sub.1 -C.sub.18 alkyl, C.sub.1 -C.sub.18 alkoxy, amino, mono-C.sub.1 -C.sub.18 alkylamino, di-C.sub.1 -C.sub.18 alkylamino, benzylamino, C.sub.1 -C.sub.18 alkylbenzylamino, C.sub.1 -C.sub.18 thioalkyl or C.sub.1 -C.sub.18 alkyl carboxamido substituent, or

R.sup.1 Y is allyloxycarbonyl or chloroacetyl;

R.sup.2 is hydrogen, C.sub.1 -C.sub.18 straight chain, branched chain or cyclic hydrocarbyl, C.sub.1 -C.sub.6 alkyl C.sub.1 -C.sub.5 alkylene .omega.-carboxylate, .omega.-tri(C.sub.1 -C.sub.4 alkyl/phenyl)silyl C.sub.2 -C.sub.4 alkylene, monosaccharide or disaccharide,

or OR.sup.2 together form a C.sub.1 -C.sub.18 straight chain, branched chain or cyclic hydrocarbyl carbamate;

R.sup.3 is hydrogen or C.sub.1 -C.sub.6 acyl;

R.sup.4 is hydrogen, C.sub.1 -C.sub.6 alkyl or benzyl;

R.sup.5 is hydrogen, benzyl, methoxybenzyl, dimethoxybenzyl or C.sub.1 -C.sub.6 acyl;

R.sup.7 is methyl or hydroxymethyl; and

X is C.sub.1 -C.sub.6 acyloxy, C.sub.2 -C.sub.6 hydroxylacyloxy, hydroxy, halo or azido.

L5 ANSWER 46 OF 80 USPATFULL

AN 96:55766 USPATFULL

TI Bis-piperidinyl non-peptidyl neurokinin receptor antagonists

IN Cho, Sung Yong S., Indianapolis, IN, United States

PA Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)

PI US 5530009 19960625

AI US 1996-462413 19960605 (8)

RLI Division of Ser. No. US 1994-271708, filed on 12 Jul 1994

DT Utility

EXNAM Primary Examiner: Chang, Ceila

LREP Gaylo, Paul J.; Boone, David E.

CLMN Number of Claims: 3

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 1027

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention provides novel compound of the formula ##STR1## which is neurokinin receptor antagonist.

L5 ANSWER 47 OF 80 USPATFULL

AN 96:46037 USPATFULL

TI Heterocyclic amides

IN Bernstein, Peter R., Wallingford, PA, United States

Shaw, Andrew, Kennett Square, PA, United States

Thomas, Royston M., Macclesfield, England

Warner, Peter, Macclesfield, England

Wolanin, Donald J., Orange, CT, United States

PA Zeneca Limited, London, England (non-U.S. corporation)

PI US 5521179 19960528

AI US 1993-45009 19930408 (8)

RLI Continuation-in-part of Ser. No. US 1992-869993, filed on 16 Apr 1992, now abandoned

DT Utility

EXNAM Primary Examiner: Ivy, C. Warren; Assistant Examiner: Compton, Raymond

LREP Alexander, Michael D.; Newton, Ruth H.; Harris, Robert J.

CLMN Number of Claims: 14

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 7408

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to certain novel heterocyclic amides which are 1-pyridylacetamide compounds of formula I, set out herein, which are inhibitors of human leukocyte elastase (HLE), also known as human neutrophil elastase (HNE), making them useful whenever such inhibition is desired, such as for research tools in pharmacological, diagnostic and related studies and in the treatment of diseases in mammals in which HLE is implicated. The invention also includes intermediates useful in the synthesis of these heterocyclic amides, processes for preparing the heterocyclic amides, pharmaceutical compositions containing such heterocyclic amides and methods for their use.

L5 ANSWER 48 OF 80 USPATFULL

AN 96:36566 USPATFULL

TI Treatment of emesis with morpholine tachykinin receptor antagonists

IN Dom, Conrad P., Plainfield, NJ, United States

MacCoss, Malcolm, Freehold, NJ, United States

Hale, Jeffrey J., Westfield, NJ, United States

Mills, Sander G., Woodbridge, NJ, United States

PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

PI US 5512570 19960430

AI US 1995-450507 19950525 (8)

RLI Division of Ser. No. US 1994-206771, filed on 4 Mar 1994

DT Utility

EXNAM Primary Examiner: Higel, Floyd D.

LREP Thies, J. Eric; Rose, David L.

CLMN Number of Claims: 15

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 6501

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Substituted heterocycles of the structural formula: ##STR1## are tachykinin receptor antagonists useful in the treatment of inflammatory diseases, pain or migraine, asthma, emesis and nausea.

L5 ANSWER 49 OF 80 USPATFULL

AN 96:27346 USPATFULL

TI PLA.sub.2 inhibitors
IN Lennon, Patrick J., Clayton, MO, United States
PA Monsanto Company, St. Louis, MO, United States (U.S. corporation)
PI US 5504237 19960402
AI US 1995-429972 19950427 (8)
RLI Division of Ser. No. US 1994-259720, filed on 14 Jun 1994, now patented,
Pat. No. US 5434288 which is a continuation-in-part of Ser. No. US
1992-984022, filed on 1 Dec 1992, now abandoned

DT Utility
EXNAM Primary Examiner: Richter, Johann; Assistant Examiner: Ambrose,
Michael
G.

LREP Goetz, Kenneth D.
CLMN Number of Claims: 19
ECL Exemplary Claim: 1,16
DRWN No Drawings
LN.CNT 1050

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB PIA.sub.2 inhibitors selected from the group consisting of ##STR1##
wherein A is selected from the group consisting of ##STR2## and Z, W,
R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8,
R.sub.9, X, X' and Y are as defined herein.

L5 ANSWER 50 OF 80 USPATFULL

AN 95:84401 USPATFULL

TI Halogenated phenylacetone nitrile alkylaminoalkylphenyl compounds as
immunosuppressives

IN Mueller, Richard A., Glencoe, IL, United States
PA G. D. Searle & Co., Chicago, IL, United States (U.S. corporation)
PI US 5451604 19950919
AI US 1993-97809 19930726 (8)

DT Utility
EXNAM Primary Examiner: Brust, Joseph Paul
LREP Keane, J. Timothy
CLMN Number of Claims: 4
ECL Exemplary Claim: 3
DRWN No Drawings
LN.CNT 5690

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A class of halogenated phenylacetone nitrile alkylaminoalkylphenyl
compounds having immunosuppressive properties is described. Compounds of
this class would be useful in reducing recipient rejection of
transplanted organs and for treatment of autoimmune or inflammatory
diseases. Compounds of particular interest are of the formula ##STR1##
wherein m is a number selected from three to five, inclusive; wherein n
one or two; wherein R.sub.1 is selected from methyl, ethyl, n-propyl,
isopropyl, n-butyl, sec-butyl, tert-butyl, iso-butyl, n-pentyl,
isopentyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,
cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl,
cyclohexylmethyl, benzyl and phenethyl; wherein R.sub.2 is selected from
methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl,
iso-butyl, n-pentyl, isopentyl, cyclopropyl, cyclobutyl, cyclopentyl,
cyclohexyl, cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl,
cyclohexylmethyl, benzyl and phenethyl; wherein each of R.sub.3 through
R.sub.7 is selected from hydrido, fluoro, chloro, bromo, azide,
trifluoromethyl, difluorochloromethyl, 1,1-difluoroethyl,
2,2,2-trifluoroethyl, perfluoroethyl and 2,2,2,3-tetrafluoropropyl; with
the proviso that at least one of R.sub.3 through R.sub.7 is selected
from fluoro and trifluoromethyl; or a tautomer thereof or a
pharmaceutically-acceptable salt thereof.

L5 ANSWER 51 OF 80 USPATFULL

AN 95:65056 USPATFULL

TI PLA.sub.2 inhibitors

IN Lennon, Patrick J., Clayton, MO, United States
PA Monsanto Company, St. Louis, MO, United States (U.S. corporation)
PI US 5434288 19950718
AI US 1994-259720 19940614 (8)

RLI Continuation-in-part of Ser. No. US 1992-984022, filed on 1 Dec 1992,
now abandoned

DT Utility
EXNAM Primary Examiner: Ramsuer, Robert W.; Assistant Examiner: Ambrose,
Michael G.

LREP Goetz, Kenneth D.; Passley, Paul L.; Bolding, James C.
CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1031

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB PLA.sub.2 inhibitors selected from the group consisting of ##STR1##
wherein A is selected from the group consisting of ##STR2## and Z, W,
R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8,
R.sub.9, X, X' and Y are as defined herein.

L5 ANSWER 52 OF 80 USPATFULL

AN 95:41068 USPATFULL

TI 1-alkyl-2-hydroxy-2-trifluoromethyl ethylamines

IN Stein, Mark M., Wilmington, DE, United States
Trainor, Diane A., Glen Mills, PA, United States

PA Zeneca Inc., Wilmington, DE, United States (U.S. corporation)
PI US 5414132 19950509

AI US 1992-940932 19920904 (7)

RLI Division of Ser. No. US 1990-491757, filed on 9 Mar 1990, now patented,
Pat. No. US 5194588 which is a division of Ser. No. US 1987-5538, filed
on 20 Jan 1987, now patented, Pat. No. US 4910190 which is a
continuation-in-part of Ser. No. US 1986-821150, filed on 21 Jan 1986,
now abandoned

PRAI GB 1985-1522 19850122

GB 1985-1523 19850122

GB 1985-1524 19850122

DT Utility

EXNAM Primary Examiner: Raymond, Richard L.

LREP Cushman Darby & Cushman

CLMN Number of Claims: 2

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 5536

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention concerns pharmaceutically useful trifluoromethyl ketone
substituted di-, tri- and tetra-peptide derivatives of the formulae Ia,
Ib, Ic set out hereinafter, and salts thereof, which are inhibitors of
human leukocyte elastase. Also described herein are pharmaceutical
compositions containing a peptide derivative and processes and
intermediates for use in the manufacture of the peptide derivatives.

L5 ANSWER 53 OF 80 USPATFULL

AN 95:13873 USPATFULL

TI 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines

IN Gerster, John F., Woodbury, MN, United States
Crooks, Stephen L., Mahtomedi, MN, United States
Lindstrom, Kyle J., Houlton, WI, United States

PA Minnesota Mining and Manufacturing Company, St. Paul, MN, United States
(U.S. corporation)

PI US 5389640 19950214

AI US 1992-938295 19920828 (7)

RLI Continuation-in-part of Ser. No. US 1992-838475, filed on 19 Feb 1992,
now abandoned which is a continuation-in-part of Ser. No. US
1991-687326, filed on 18 Apr 1991, now abandoned which is a
continuation-in-part of Ser. No. US 1991-662926, filed on 1 Mar 1991,
now abandoned

DT Utility

EXNAM Primary Examiner: Rotman, Alan L.

LREP Griswold, Gary L.; Kim, Walter N.; Reedich, Douglas E.

CLMN Number of Claims: 15

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 2463

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines are
disclosed. These compounds function as antiviral agents, they induce
biosynthesis of interferon, and they inhibit tumor formation in animal
models. This invention also provides intermediates for preparing such
compounds, pharmaceutical compositions containing such compounds, and
pharmacological methods of using such compounds.

L5 ANSWER 54 OF 80 USPATFULL

AN 93:89678 USPATFULL

TI Azabicyclic compounds, pharmaceutical compositions containing them and
their use in therapy

IN Ladduwahetty, Tamara, Buckhurst Hill, England
Swain, Christopher J., Duxford, England

PA Merck Sharp & Dohme, Limited, Hoddlesdon, England (non-U.S. corporation)

PI US 5256671 19931026

AI US 1992-905974 19920629 (7)

DT Utility

EXNAM Primary Examiner: Tsang, Cecilia

LREP North, Robert J.; Caruso, Charles M.; DiPrima, Joseph F.
 CLMN Number of Claims: 12
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN.CNT 1061
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Compounds of formula (I), and salts and prodrugs thereof: ##STR1##
 wherein Q is the residue of an optionally substituted azabicyclic ring system;
 the dotted line represents an optional double bond;
 X represents H, --OH, -dbd.O or halo;
 R.sup.1 represents H, phenyl or thienyl, which phenyl or thienyl groups may be optionally substituted by halo or trifluoromethyl;
 R.sup.2 represents phenyl, thienyl or benzyl, any of which groups may be optionally substituted by halo or trifluoromethyl; and
 R.sup.3, R.sup.4 and R.sup.5 independently represent H, C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, halo, cyano, nitro, trifluoromethyl, trimethylsilyl, --OR.sup.a, SR.sup.a, SOR.sup.a, SO.sub.2 R.sup.a, --NR.sup.a R.sup.b, --NR.sup.a COR.sup.b, --NR.sup.a CO.sub.2 R.sup.b, --CO.sub.2 R.sup.a or --CONR.sup.a R.sup.b; and
 R.sup.a and R.sup.b independently represent H, C.sub.1-6 alkyl, phenyl or trifluoromethyl, are tachykinin receptor antagonists. They and compositions thereof are useful in therapy.

L5 ANSWER 55 OF 80 USPATFULL
 AN 93:82882 USPATFULL
 TI Indole-, benzofuran-, and benzothiophene-containing lipoxygenase-inhibiting compounds
 IN Brooks, Dee W., Libertyville, IL, United States
 Summers, James B., Libertyville, IL, United States
 PA Abbott Laboratories, Abbott Park, IL, United States (U.S. corporation)
 PI US 5250565 19931005
 AI US 1992-823411 19920121 (7)
 DCD 20061010
 RLI Continuation of Ser. No. US 1990-572451, filed on 28 Aug 1990, now abandoned which is a continuation-in-part of Ser. No. US 1989-404300, filed on 7 Sep 1989, now abandoned which is a continuation-in-part of Ser. No. US 1988-138073, filed on 11 Jan 1988, now patented, Pat. No. US 4873259 which is a continuation-in-part of Ser. No. US 1987-60784, filed on 10 Jun 1987, now abandoned which is a continuation-in-part of Ser. No. US 1987-12970, filed on 10 Feb 1987, now abandoned
 DT Utility
 EXNAM Primary Examiner: Siegel, Alan
 LREP Janssen, Jerry F.
 CLMN Number of Claims: 3
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN.CNT 764
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Pro-drugs of potent 5-lipoxygenase inhibiting compounds comprise compounds of the formula ##STR1## in which A is an alkylene or alkenylene group, X is oxygen, sulfur, sulfoxyl, or substituted nitrogen, and Y is a group which includes substituted or unsubstituted carbocyclic or substituted or unsubstituted heterocyclic aryl. R.sup.1 is an alkyl, alkenyl, amino, alkylamino, dialkylamino, or hydroxyamino group or an amine group bearing a metabolically cleavable leaving group. M is hydrogen, a pharmaceutically acceptable cation or a metabolically cleavable leaving group, with the proviso that either M or R.sup.1 must bear a metabolically cleavable leaving group.

L5 ANSWER 56 OF 80 USPATFULL
 AN 93:20683 USPATFULL
 TI Aminoalcohol intermediates for peptide derivatives
 IN Edwards, Philip D., Claymont, DE, United States
 PA ICI Americas Inc., Wilmington, DE, United States (U.S. corporation)
 PI US 5194588 19930316
 AI US 1990-491757 19900309 (7)
 RLI Division of Ser. No. US 1987-5538, filed on 20 Jan 1987, now patented, Pat. No. US 4910190 which is a continuation-in-part of Ser. No. US 1986-821150, filed on 21 Jan 1986, now abandoned
 PRAI GB 1985-1522 19850122
 GB 1985-1523 19850122
 GB 1985-1524 19850122
 DT Utility
 EXNAM Primary Examiner: Lee, Lester L.
 LREP Miano, Rosemary M.; Jackson, Thomas E.
 CLMN Number of Claims: 7
 ECL Exemplary Claim: 1

DRWN No Drawings
 LN.CNT 5515
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB The invention concerns pharmaceutically useful trifluoromethyl ketone substituted di-, tri- and tetra-peptide derivatives of the formulae Ia, Ib, Ic set out hereinafter, and salts thereof, which are inhibitors of human leukocyte elastase. Also described herein are pharmaceutical compositions containing a peptide derivative and processes and intermediates for use in the manufacture of the peptide derivatives.

L5 ANSWER 57 OF 80 USPATFULL
 AN 92:72472 USPATFULL
 TI Halomacrolides and derivatives having immunosuppressive activity
 IN Bochis, Richard J., East Brunswick, NJ, United States
 Wyvratt, Jr., Matthew J., Mountainside, NJ, United States
 PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
 PI US 5143918 19920901
 AI US 1991-759747 19910912 (7)
 RLI Continuation of Ser. No. US 1990-596177, filed on 11 Oct 1990, now abandoned
 DT Utility
 EXNAM Primary Examiner: Bond, Robert T.
 LREP Caruso, Charles M.; North, Robert J.; Thies, J. Eric
 CLMN Number of Claims: 9
 ECL Exemplary Claim: 1,9
 DRWN No Drawings
 LN.CNT 2003
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Novel C-3" and C-4" halogen-substituted macrolides of FK-506 type structural Formula I: ##STR1## are described. These macrolide immunosuppressants are useful in a mammalian host for the treatment of autoimmune diseases (such as juvenile-onset diabetes melitus, multiple sclerosis and rheumatoid arthritis), infectious diseases and/or the prevention of rejection of foreign organ transplants, e.g. bone marrow and heart transplants. In addition, these macrolide immunosuppressants are useful in the topical treatment of inflammatory and hyperproliferative skin diseases and cutaneous manifestations of immunologically-mediated illnesses such as: psoriasis, atopic dermatitis, contact dermatitis and further eczematous dermatitis, seborrheic dermatitis, Lichen planus, Pemphigus, bullous Pemphigoid, Epidermolysis bullosa, urticaria, angioedemas, vasculitides erythemas, cutaneous eosinophilias, Lupus erythematosus or Alopecia areata.

L5 ANSWER 58 OF 80 USPATFULL
 AN 92:68332 USPATFULL
 TI Amine derivatives of folic acid analogs
 IN Coughlin, Daniel J., Robbinsville, NJ, United States
 Rodwell, John D., Yardley, PA, United States
 PA CytoGen Corporation, NJ, United States (U.S. corporation)
 PI US 5140104 19920818
 AI US 1989-426374 19891024 (7)
 RLI Continuation of Ser. No. US 1986-861037, filed on 8 May 1986, now abandoned which is a continuation-in-part of Ser. No. US 1984-650375, filed on 13 Sep 1984, now patented, Pat. No. US 4867973 Ser. No. Ser. No. US 1984-650754, filed on 13 Sep 1984, now abandoned Ser. No. Ser. No. US 1984-646327, filed on 31 Aug 1984, now abandoned Ser. No. Ser. No. US 1984-646328, filed on 31 Aug 1984, now patented, Pat. No. US 4741900 And Ser. No. US 1982-356315, filed on 9 Mar 1982, now patented, Pat. No. US 4671958
 DT Utility
 EXNAM Primary Examiner: Waddell, Frederick E.; Assistant Examiner: Weddington, K.
 LREP Pennie & Edmonds
 CLMN Number of Claims: 10
 ECL Exemplary Claim: 1
 DRWN 2 Drawing Figure(s); 2 Drawing Page(s)
 LN.CNT 1476
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Novel therapeutic antibody conjugates comprising amine derivatives of folic acid analogs covalently attached via a reactive amine group to an oxidized carbohydrate moiety of an antibody or antibody fragment are disclosed. The conjugates retain substantially the same immunospecificity and immunoreactivity of the unconjugated antibody molecule. The immunospecificity and immunoreactivity of the antibody conjugates permits targeted delivery of the attached therapeutically effective amine derivative of folic acid analogs in vivo. The conjugates

are therapeutically effective against a variety of neoplastic and non-neoplastic cellular disorders when administered in vivo. Methods for synthesizing the amine derivatives of folic acid analogs, methods for preparing the antibody conjugates, and methods for use of the conjugates in vivo are also disclosed.

L5 ANSWER 59 OF 80 USPATFULL

AN 92:59870 USPATFULL

TI Substituted cephalosporin sulfones as anti-inflammatory and anti-degenerative agents

IN Doherty, James B., New Milford, NJ, United States

Firestone, Raymond A., Westfield, NJ, United States

Finke, Paul E., Milltown, NJ, United States

Hagmann, William K., Westfield, NJ, United States

Shah, Shrenik K., Metuchen, NJ, United States

Thompson, Kevan R., Westfield, NJ, United States

PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

PI US 5132301 19920721

AI US 1990-471320 19900129 (7)

RLI Continuation of Ser. No. US 1986-930193, filed on 12 Nov 1986, now abandoned which is a continuation-in-part of Ser. No. US 1985-774425, filed on 10 Sep 1985, now abandoned which is a continuation-in-part of Ser. No. US 1983-490761, filed on 2 May 1983, now abandoned

DT Utility

EXNAM Primary Examiner: Rizzo, Nicholas S.

LREP Panzer, Curtis C.; Pfeiffer, Hesna J.

CLMN Number of Claims: 6

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 2147

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB New substituted cephalosporin sulfones are found to be potent elastase inhibitors and thereby useful anti-inflammatory/antidegenerative agents.

L5 ANSWER 60 OF 80 USPATFULL

AN 91:82198 USPATFULL

TI Peptide derivatives

IN Edwards, Philip D., Claymont, DE, United States

Schwartz, John A., Wilmington, all, DE, United States

Stein, Mark M., Wilmington, all, DE, United States

Trainor, Diane A., Glen Mills, PA, United States

Wildonger, Richard A., Elmwood, DE, United States

PA ICI Americas Inc., Wilmington, DE, United States (U.S. corporation)

PI US 5055450 19911008

AI US 1990-493025 19900313 (7)

RLI Division of Ser. No. US 1987-5538, filed on 20 Jan 1987, now patented, Pat. No. US 4910190 which is a continuation-in-part of Ser. No. US 1986-821150, filed on 21 Jan 1986, now abandoned

PRAI GB 1985-1522 19850122

GB 1985-1523 19850122

GB 1985-1524 19850122

DT Utility

EXNAM Primary Examiner: Lee, Lester L.; Assistant Examiner: Davenport, Avis

LREP Miano, Rosemary M.; Jackson, Thomas E.

CLMN Number of Claims: 7

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 6077

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention concerns pharmaceutically useful trifluoromethyl ketone substituted di-, tri- and tetra-peptide derivatives of the formulae Ia, Ib, Ic set out hereinafter, and salts thereof, which are inhibitors of human leukocyte elastase. Also described herein are pharmaceutical compositions containing a peptide derivative and processes and intermediates for use in the manufacture of the peptide derivatives.

L5 ANSWER 61 OF 80 USPATFULL

AN 91:46724 USPATFULL

TI Substituted 1-H-pyrrolopyridine-3-carboxamides

IN Scherlock, Margaret H., Bloomfield, NJ, United States

Tom, Wing C., Cedar Grove, NJ, United States

PA Schering Corporation, Kenilworth, NJ, United States (U.S. corporation)

PI US 5023265 19910611

AI US 1990-532304 19900601 (7)

DT Utility

EXNAM Primary Examiner: Dentz, Bernard I.

LREP Nelson, James R.

CLMN Number of Claims: 11

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 755

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Substituted 1H-pyrrolopyridine-3-carboxamides and their use in pharmaceutical compositions and in treating inflammation are disclosed.

L5 ANSWER 62 OF 80 USPATFULL

AN 90:69866 USPATFULL

TI Leukotriene by amides and hydrazides

IN Young, Robert N., Senneville, Canada

Rokach, Joshua, Chemedey, Laval, Canada

Hayes, Edward C., Lincroft, NJ, United States

PA Merck Frosst Canada, Inc., Kirkland, Canada (non-U.S. corporation)

Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

PI US 4954638 19900904

AI US 1988-227038 19880801 (7)

RLI Division of Ser. No. US 1986-859971, filed on 5 May 1986, now patented, Pat. No. US 4767745 which is a continuation of Ser. No. US 1984-665596, filed on 29 Oct 1984, now abandoned which is a continuation-in-part of Ser. No. US 1983-565263, filed on 17 Dec 1983, now abandoned which is a continuation-in-part of Ser. No. US 1982-370229, filed on 20 Apr 1982, now abandoned And a continuation-in-part of Ser. No. US 1983-560663, filed on 12 Dec 1983, now abandoned

DT Utility

EXNAM Primary Examiner: Phillips, Delbert R.; Assistant Examiner: Perkins, Susan M.

LREP Lopez, Gabriel; Pfeiffer, Hesna J.

CLMN Number of Claims: 4

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 677

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Leukotrienes may be conjugated with various proteins such as Bovine Serum Albumin (BSA) and Hemocyanin from Giant Keyhole Limpets (KLH) using 1,5-difluoro-2,4-dinitrobenzene or 6-N-maleimidohexanoic acid chloride as coupling agents.

These conjugates are useful as reagents in a newly developed immunoassay for leukotrienes, as well as having potential utility as chemical immunotherapeutic agents in the treatment of various allergic and chronic inflammatory diseases of the skin, lung, and airways, including asthma, allergic rhinitis, rheumatoid arthritis, and skin diseases such as psoriasis and eczema.

L5 ANSWER 63 OF 80 USPATFULL

AN 90:21543 USPATFULL

TI Peptide derivatives

IN Bergeson, Scott H., Wilmington, DE, United States

PA ICI Americas Inc., Wilmington, DE, United States (U.S. corporation)

PI US 4910190 19900320

AI US 1987-5538 19870120 (7)

RLI Continuation-in-part of Ser. No. US 1986-821150, filed on 21 Jan 1986, now abandoned

PRAI GB 1985-1522 19850122

GB 1985-1523 19850122

GB 1985-1524 19850122

DT Utility

EXNAM Primary Examiner: Phillips, Delbert R.

LREP Miano, Rosemary M.; Jackson, Thomas E.

CLMN Number of Claims: 9

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 5524

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention concerns pharmaceutically useful trifluoromethyl ketone substituted di-, tri- and tetra-peptide derivatives of the formulae Ia, Ib, Ic set out hereinafter, and salts thereof, which are inhibitors of human leukocyte elastase. Also described herein are pharmaceutical compositions containing a peptide derivative and processes and intermediates for use in the manufacture of the peptide derivatives.

L5 ANSWER 64 OF 80 USPATFULL

AN 90:7700 USPATFULL

TI Lipxygenase inhibiting compounds

IN Summers, Jr., James B., Libertyville, IL, United States

PA Abbott Laboratories, Abbott Park, IL, United States (U.S. corporation)

PI US 4897422 19900130

AI US 1987-12978 19870210 (7)
DT Utility
EXNAM Primary Examiner: Evans, J. E.
LREP Stevenson, Robert W.; Weinstock, Steven F.; Crowley, Steven R.
CLMN Number of Claims: 6
ECL Exemplary Claim: 1,4
DRWN No Drawings
LN.CNT 598

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds of the formula: ##STR1## where R.sub.1 is amino or methyl;
R.sub.2 is C.sub.1 -C.sub.2 alkyl; R.sub.3 is one or more substituents
selected from hydrogen, halogen or trihalomethyl; R.sub.4 is one or more
substituents selected from hydrogen, halogen, trihalomethyl, C.sub.1 to
C.sub.4 alkoxy or C.sub.1 to C.sub.4 alkyl; and M is hydrogen, a
pharmaceutically acceptable cation, aryl, or C.sub.1 to C.sub.6 alkyl
are inhibitors of 5- and/or 12-lipoxygenase enzymes.

L5 ANSWER 65 OF 80 USPATFULL

AN 89:84272 USPATFULL

TI Indole, benzofuran, benzothiophene containing lipoxygenase inhibiting
compounds

IN Summers, Jr., James B., Libertyville, IL, United States

Gunn, Bruce P., Island Lake, IL, United States

Brooks, Dee W., Libertyville, IL, United States

PA Abbott Laboratories, Abbott Park, IL, United States (U.S. corporation)

PI US 4873259 19891010

AI US 1988-138073 19880111 (7)

RLI Continuation-in-part of Ser. No. US 1987-60784, filed on 10 Jun 1987,
now abandoned which is a continuation-in-part of Ser. No. US 1987-12970,
filed on 10 Feb 1987, now abandoned

DT Utility

EXNAM Primary Examiner: Siegel, Alan

LREP Weinstock, Steven F.; Crowley, Steven R.; Katz, Martin L.

CLMN Number of Claims: 25

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 1764

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds of the formula: ##STR1## wherein R.sub.1 is (1) hydrogen, (2)
C.sub.1 to C.sub.4 alkyl, (3) C.sub.2 to C.sub.4 alkenyl, or (4)
NR.sub.2 R.sub.3, wherein R.sub.2 and R.sub.3 are independently selected from
(1) hydrogen, (2) C.sub.1 to C.sub.4 alkyl and (3) hydroxyl, but
R.sub.2 and R.sub.3 are not simultaneously hydroxyl;

wherein X is oxygen, sulfur, SO.sub.2, or NR.sub.4, wherein R.sub.4 is
(1) hydrogen, (2) C.sub.1 to C.sub.6 alkyl, (3) C.sub.1 to C.sub.6
alkoyl, (4) aryl, or (5) alkylsulfonyl;

A is selected from C.sub.1 to C.sub.6 alkylene and C.sub.2 to C.sub.6
alkenylene;
n is 1-5;

Y is selected independently at each occurrence from (1) hydrogen, (2)
halogen, (3) hydroxy, (4) cyano, (5) halosubstituted alkyl, (6) C.sub.1
to C.sub.12 alkyl, (7) C.sub.2 to C.sub.12 alkenyl, (8) C.sub.1 to
C.sub.12 alkoxy, (9) C.sub.3 to C.sub.8 cycloalkyl, (10) C.sub.1
-C.sub.8 thioalkyl, (11) aryl, (12) aryloxy, (13) aryl, (14) C.sub.1 to
C.sub.12 arylalkyl, (15) C.sub.2 to C.sub.12 arylalkenyl, (16) C.sub.1
to C.sub.12 arylalkoxy, (17) C.sub.1 to C.sub.12 arylthioalkoxy, and
substituted derivatives of (18) aryl, (19) aryloxy, (20) aryl, (21)
C.sub.1 to C.sub.12 arylalkyl, (22) C.sub.2 to C.sub.12 arylalkenyl,
(23) C.sub.1 to C.sub.12 arylalkoxy, or (24) C.sub.1 to C.sub.12
arylthioalkoxy, wherein substituents are selected from halo, nitro,
cyano, C.sub.1 to C.sub.12 alkyl, alkoxy, and halosubstituted alkyl;
Z is oxygen or sulfur;
and M is hydrogen, a pharmaceutically acceptable cation, aryl, or
C.sub.1 to C.sub.12 alkyl, are potent inhibitors of 5- and/or
12-lipoxygenase enzymes.

Also disclosed are lipoxygenase inhibiting compositions and a method for
inhibiting lipoxygenase activity.

L5 ANSWER 66 OF 80 USPATFULL

AN 89:34405 USPATFULL

TI 6,11-Dihydro-11-(N-substituted-4-piperidylidene)-5H-
benzo[5,6]cyclohepta[1,2-B]pyridines and compositions and methods of use

IN Piwinski, John J., Parsippany, NJ, United States

Ganguly, Ashit K., Upper Montclair, NJ, United States

Green, Michael J., Skillman, NJ, United States

Villani, Frank J., Fairfield, NJ, United States

Wong, Jesse, Union, NJ, United States

PA Schering Corporation, Kenilworth, NJ, United States (U.S. corporation)

PI US 4826853 19890502

AI US 1986-925342 19861031 (6)

DT Utility

EXNAM Primary Examiner: Lee, Mary C.; Assistant Examiner: Northington, Zinna

LREP Nowak, Henry P.; Billups, Richard C.; Nelson, James R.

CLMN Number of Claims: 29

ECL Exemplary Claim: 1,21

DRWN No Drawings

LN.CNT 1413

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Derivatives of 6,11-dihydro-11-(4-piperidylidene)-5H-
benzo[5,6]cyclohepta[1,2-b]pyridine, and pharmaceutically acceptable
salts and solvates thereof are disclosed, which possess anti-allergic
and anti-inflammatory activity. Methods for preparing and using the
compounds are also described.

L5 ANSWER 67 OF 80 USPATFULL

AN 89:30123 USPATFULL

TI Benzazole lipoxygenase inhibiting compounds

IN Summers, James B., Libertyville, IL, United States

Stewart, Andrew O., Libertyville, IL, United States

PA Abbott Laboratories, Abbott Park, IL, United States (U.S. corporation)

PI US 4822809 19890418

AI US 1987-120251 19871113 (7)

DT Utility

EXNAM Primary Examiner: Schwartz, Richard A.

LREP Crowley, Steven R.; Weinstock, Steven F.; Katz, Martin L.

CLMN Number of Claims: 12

ECL Exemplary Claim: 1,11

DRWN No Drawings

LN.CNT 648

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds of the formula: ##STR1## wherein R.sub.1 is (1) hydrogen, (2)
C.sub.1 to C.sub.4 alkyl, (3) C.sub.2 to C.sub.4 alkenyl, or (4)
NR.sub.2 R.sub.3, wherein R.sub.2 and R.sub.3 are independently selected
from (1) hydrogen, (2) C.sub.1 to C.sub.4 alkyl and (3) hydroxyl, but
R.sub.2 and R.sub.3 are not simultaneously hydroxyl;

X is (1) oxygen, (2) sulfur, (3) SO.sub.2, or (4) NR.sub.4, wherein
R.sub.4 is (1) hydrogen, (2) C.sub.1 to C.sub.6 alkyl, (3) C.sub.1 to
C.sub.6 alkyl or (4) aryl;

A is selected from C.sub.1 to C.sub.6 alkylene and C.sub.2 to C.sub.6
alkenylene; n is 0-4;

Y is selected independently at each occurrence from (1) hydrogen, (2)
halogen, (3) hydroxy, (4) cyano, (5) halosubstituted alkyl, (6) C.sub.1
to C.sub.12 alkyl, (7) C.sub.2 to C.sub.12 alkenyl, (8) C.sub.1 to
C.sub.12 alkoxy, (9) C.sub.3 to C.sub.8 cycloalkyl, (10) aryl, (11)
aryloxy, (12) aryl, (13) C.sub.1 to C.sub.12 arylalkyl, (14) C.sub.2 to
C.sub.12 arylalkenyl, (15) C.sub.1 to C.sub.12 arylalkoxy, (16) C.sub.1
to C.sub.12 arylthioalkoxy, and substituted derivatives of (17) aryl,
(18) aryloxy, (19) aryl, (20) C.sub.1 to C.sub.12 arylalkyl, (21)
C.sub.2 to C.sub.12 arylalkenyl, (22) C.sub.1 to C.sub.12 arylalkoxy, or
(23) C.sub.1 to C.sub.12 arylthioalkoxy, wherein substituents are
selected from halo, nitro, cyano, C.sub.1 to C.sub.12 alkyl, alkoxy, and
halosubstituted alkyl;

and M is hydrogen, a pharmaceutically acceptable cation, aryl, or
C.sub.1 to C.sub.12 alkyl, are potent inhibitors of 5- and/or
12-lipoxygenase enzymes. Also disclosed are lipoxygenase inhibiting
compositions and a method for inhibiting lipoxygenase.

L5 ANSWER 68 OF 80 USPATFULL

AN 88:57307 USPATFULL

TI Dibenzofuran lipoxygenase inhibiting compounds, compositions and use

IN Summers, James B., Libertyville, IL, United States

Moore, Jimmie L., Gurnee, IL, United States

PA Abbott Laboratories, Abbott Park, IL, United States (U.S. corporation)

PI US 4769387 19880906

AI US 1987-120301 19871113 (7)

DT Utility

EXNAM Primary Examiner: Ramsuer, Robert W.

LREP Crowley, Steven R.; Weinstock, Steven F.; Katz, Martin L.

CLMN Number of Claims: 9

ECL Exemplary Claim: 1,9

DRWN No Drawings

LN.CNT 691

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds of the formula: ##STR1## wherein R.sub.1 is (1) hydrogen, (2) C.sub.1 to C.sub.4 alkyl, (3) C.sub.2 to C.sub.4 alkenyl, or (4) NR.sub.2 R.sub.3, wherein R.sub.2 and R.sub.3 are independently selected from hydrogen, C.sub.1 to C.sub.4 alkyl and hydroxyl, but R.sub.2 and R.sub.3 are not simultaneously hydroxyl;

X is (1) oxygen, (2) sulfur, (3) SO.sub.2, or (4) NR.sub.4, wherein R.sub.4 is (1) hydrogen, (2) C.sub.1 to C.sub.6 alkyl, (3) C.sub.1 to C.sub.6 alkoyl or (4) aroyl;

A is selected from C.sub.1 to C.sub.6 alkylene and C.sub.2 to C.sub.6 alkenylene;

n is 0-4;

Y is selected independently at each occurrence from (1) hydrogen, (2) halogen, (3) hydroxy, (4) cyano, (5) halosubstituted alkyl, (6) C.sub.1 to C.sub.12 alkyl, (7) C.sub.2 to C.sub.12 alkenyl, (8) C.sub.1 to C.sub.12 alkoxy, (9) C.sub.3 to C.sub.8 cycloalkyl, (10) aryl, (11) aryloxy, (12) aroyl, (13) C.sub.1 to C.sub.12 arylalkyl, (14) C.sub.2 to C.sub.12 arylalkenyl, (15) C.sub.1 to C.sub.12 arylalkoxy, (16) C.sub.1 to C.sub.12 arylthioalkoxy, and substituted derivatives of (17) aryl, (18) aryloxy, (19) aroyl, (20) C.sub.1 to C.sub.12 arylalkyl, (21) C.sub.2 to C.sub.12 arylalkenyl, (22) C.sub.1 to C.sub.12 arylalkoxy, or (23) C.sub.1 to C.sub.12 arylthioalkoxy, wherein substituents are selected from halo, nitro, cyano, C.sub.1 to C.sub.12 alkyl, alkoxy, and halosubstituted alkyl;

and M is hydrogen, a pharmaceutically acceptable cation, aroyl, or C.sub.1 to C.sub.12, alkoyl are potent inhibitors of 5- and/or 12-lipoxygenase enzymes. Also disclosed are lipoxygenase inhibiting compositions and a method of inhibiting lipoxygenase.

L5 ANSWER 69 OF 80 USPATFULL

AN 88:5539 USPATFULL

TI Conjugates of leukotrienes with proteins

IN Young, Robert N., Senneville, Canada

Rokach, Joshua, Chomedey-Laval, Canada

Hayes, Edward C., Lincroft, NJ, United States

PA Merck Frost Canada, Inc., Kirkland, Canada (non-U.S. corporation)

Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

PI US 4767745 19880830

AI US 1986-859971 19860505 (6)

RLI Continuation of Ser. No. US 1984-665596, filed on 29 Oct 1984, now abandoned which is a continuation-in-part of Ser. No. US 1983-565263, filed on 17 Dec 1983, now abandoned which is a continuation-in-part of Ser. No. US 1982-370229, filed on 20 Apr 1982, now abandoned And a continuation-in-part of Ser. No. US 1983-560663, filed on 12 Dec 1983, now abandoned

DT Utility

EXNAM Primary Examiner: Phillips, Delbert R.

LREP Lopez, Gabriel; Pfeiffer, Hesna J.

CLMN Number of Claims: 8

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 701

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Leukotrienes may be conjugated with various proteins such as Bovine Serum Albumin (BSA) and Hemocyanin from Giant Keyhole Limpets (KLH) using 1,5-difluoro-2,4-dinitrobenzene or 6-N-maleimidohehexanoic acid chloride as coupling agents.

These conjugates are useful as reagents in a newly developed immunoassay for leukotrienes, as well as having potential utility as chemical immunotherapeutic agents in the treatment of various allergic and chronic inflammatory diseases of the skin, lung, and airways, including asthma, allergic rhinitis, rheumatoid arthritis, and skin diseases such as psoriasis and eczema.

L5 ANSWER 70 OF 80 USPATFULL

AN 87:4879 USPATFULL

TI Substituted cephalosporins as anti-inflammatory and antidegenerative agents

IN Doherty, James B., New Milford, NJ, United States

Finke, Paul E., Metuchen, NJ, United States

Firestone, Raymond A., Fanwood, NJ, United States

Shah, Shrenik S., Clark, NJ, United States

Thompson, Kevan R., Westfield, NJ, United States

PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

PI US 4637999 19870120

AI US 1983-490617 19830502 (6)

DT Utility

EXNAM Primary Examiner: Rizzo, Nicholas S.

LREP Cheng, Theresa Y.; Sudol, Michael C.

CLMN Number of Claims: 8

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 1550

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Substituted cephalosporins are found to be potent elastase inhibitors and thereby useful antiinflammatory/antidegenerative agents.

L5 ANSWER 71 OF 80 USPATFULL

AN 85:61082 USPATFULL

TI Conformationally restricted thymopentin-like compounds

IN Goldstein, Gideon, Short Hills, NJ, United States

Heavner, George, Flemington, NJ, United States

Audhya, Tapan, Bridgewater, NJ, United States

Tjoeng, Foe-Siong, Neshanic Station, NJ, United States

PA Ortho Pharmaceutical Corporation, Raritan, NJ, United States (U.S. corporation)

PI US 4547489 19851015

AI US 1984-618968 19840611 (6)

DT Utility

EXNAM Primary Examiner: Phillips, Delbert R.

LREP Dellenbaugh, Geoffrey G.

CLMN Number of Claims: 9

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 1092

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Immunoregulating peptides are disclosed which are cyclic peptides similar to thymopentin. These peptides are useful for their effects on the immune system, especially the treatment of thymic deficiencies.

L5 ANSWER 72 OF 80 USPATFULL

AN 85:4928 USPATFULL

TI Pyridyl-substituted-benzofurans

IN Johnson, Roy A., Norfolk County, MA, United States

PA The Upjohn Company, Kalamazoo, MI, United States (U.S. corporation)

PI US 4495357 19850122

AI US 1982-430306 19820930 (6)

RLI Continuation-in-part of Ser. No. US 1982-385622, filed on 8 Jun 1982, now abandoned which is a continuation-in-part of Ser. No. US 1981-279374, filed on 1 Jul 1981, now abandoned

DT Utility

EXNAM Primary Examiner: Rotman, Alan L.; Assistant Examiner: Dentz, Bernard I.

LREP Welch, Lawrence T.

CLMN Number of Claims: 33

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 1943

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides novel pyridinyl-benzofurans and derivatives thereof which are useful as thromboxane A.sub.2 (TXA.sub.2) synthetase inhibitors and as such represent potent pharmacological agents.

L5 ANSWER 73 OF 80 USPATFULL

AN 81:34511 USPATFULL

TI Modulating the immune response with 2-substituted-3-hydroxythiazolo[2,3-b]be

IN Wei, Peter H. L., Springfield, PA, United States

Gregory, Francis J., Berwyn, PA, United States

PA American Home Products Corporation, New York, NY, United States (U.S. corporation)

PI US 4275065 19810623

AI US 1980-130483 19800331 (6)

RLI Continuation-in-part of Ser. No. US 1979-50847, filed on 21 Jun 1979, now abandoned

DT Utility

EXNAM Primary Examiner: Schwartz, Richard A.

LREP Tarnowski, George

CLMN Number of Claims: 18

ECL Exemplary Claim: 18

DRWN No Drawings

LN.CNT 847

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel 2-substituted-3-hydroxythiazolo[2,3-b]benzo-(and azabenzothiazolium salts, the mesoionic dihydro derivatives thereof and related compounds are disclosed, as well as the use thereof as modulators of the immune response.

L5 ANSWER 74 OF 80 USPATFULL

AN 80:65783 USPATFULL

TI Bradykinin-inhibiting tripeptide derivatives

IN Claesson, Karl G., Lidingö, Sweden

Simonsson, Leif R., Hisings-Backa, Sweden

Arielly, Salo, Kungsbacka, Sweden

PA AB Kabi, Stockholm, Sweden (non-U.S. corporation)

PI US 4242329 19801230

AI US 1979-58333 19790717 (6)

PRAI SE 1978-7937 19780718

DT Utility

EXNAM Primary Examiner: Phillips, Delbert R.

LREP Pollock, Vande Sande & Priddy

CLMN Number of Claims: 24

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 491

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Tripeptide derivatives of the formula

H-D-X-Phe-Arg-Y

in which

X is selected from the group consisting of Pro and Phe

Y is selected from the group consisting of O--R.sub.1 and NH--R.sub.2 in which

R.sub.1 is selected from the group consisting of straight, branched and

cyclic alkyl group with 1-12 C atoms, and

R.sub.2 is selected from the group consisting of H, straight, branched

and cyclic alkyl group with 1-12 C atoms, and physiologically acceptable salts

thereof.

A process for producing said tripeptide derivatives by synthesis and

purification methods which are known in the peptide chemistry.

harmaceutical preparations comprising said tripeptide derivatives.

L5 ANSWER 75 OF 80 USPATFULL

AN 78:43916 USPATFULL

TI 1,3-Benzodithiolanes

IN Sprague, Peter W., Titusville, NJ, United States

Heikes, James E., East Windsor, NJ, United States

PA E. R. Squibb & Sons, Inc., Princeton, NJ, United States (U.S. corporation)

PI US 4107175 19780815

AI US 1976-751552 19761217 (5)

RLI Division of Ser. No. US 1976-705849, filed on 16 Jul 1976, now Defensive Publication No.

DT Utility

EXNAM Primary Examiner: Jaisle, Cecilia M.

LREP Levinson, Lawrence S.; Smith, Merle J.; Barrack, Donald J.

CLMN Number of Claims: 21

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 1227

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds having the formula ##STR1## and the pharmaceutically acceptable salts thereof, wherein R.sub.1 is hydrogen, halogen, trifluoromethyl, alkyl, alkoxy, nitro, amino, or hydroxy; R.sub.2 is carboxyl or alkoxycarbonyl; and n is 0, 1, 2, 3, 4 or 5; have antiinflammatory activity.

L5 ANSWER 76 OF 80 USPATFULL

AN 78:40990 USPATFULL

TI 1,3-Benzodithiolanes

IN Sprague, Peter W., Titusville, NJ, United States

Heikes, James E., East Windsor, NJ, United States

PA E. R. Squibb & Sons, Inc., Princeton, NJ, United States (U.S. corporation)

PI US 4104467 19780801

AI US 1976-705849 19760716 (5)

DT Utility

EXNAM Primary Examiner: Coughlan, Jr., Paul M.

LREP Levinson, Lawrence S.; Smith, Merle J.; Barrack, Donald J.

CLMN Number of Claims: 23

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 1253

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds having the formula ##STR1## and the pharmaceutically acceptable salts thereof, wherein R.sub.1 is hydrogen, halogen, trifluoromethyl, alkyl, alkoxy, nitro, amino, or hydroxy; and R.sub.2 is an amino group, a 5- or 6-membered heterocyclic group, a 3-indolyl group, carboxyl, or alkoxycarbonyl; and n is 0, 1, 2, 3, 4 or 5; have antiinflammatory activity.

L5 ANSWER 77 OF 80 USPATFULL

AN 77:22467 USPATFULL

TI 9-Deoxy-9.alpha.-hydroxymethyl-PGF.sub.2 analogs

IN Bundy, Gordon L., Kalamazoo, MI, United States

PA The Upjohn Company, Kalamazoo, MI, United States (U.S. corporation)

PI US 4021467 19770503

AI US 1976-651622 19760123 (5)

RLI Division of Ser. No. US 1975-556768, filed on 10 Mar 1975, now patented, Pat. No. US 3950363

DT Utility

EXNAM Primary Examiner: Gerstl, Robert

LREP Spaeth, Earl C.; Armitage, Robert A.

CLMN Number of Claims: 10

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 2126

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The disclosure includes novel cyclic ethers of the formulas: ##STR1## In these formulas, X and Y are --O-- or a valence bond with the proviso that one of X and Y is --O-- and the other is a valence bond; R is hydrogen, alkyl of one to 4 carbon atoms; inclusive, or a pharmacologically acceptable cation; R.sub.2 and R.sub.3 are hydrogen, methyl, or ethyl; and A is ##STR2## wherein R.sub.4 is hydrogen, methyl, or ethyl with the proviso that R.sub.2 and R.sub.3 are both hydrogen when R.sub.4 is methyl or ethyl. The compounds of the first of these formulas are useful as vasoconstrictors and enhancers of platelet aggregation, and are useful in the control of bleeding in mammals, including man. The compounds of the second of these formulas are useful in the treatment of inflammation.

L5 ANSWER 78 OF 80 USPATFULL

AN 76:20185 USPATFULL

TI Prostaglandin cyclic ethers

IN Bundy, Gordon L., Kalamazoo, MI, United States

PA The Upjohn Company, Kalamazoo, MI, United States (U.S. corporation)

PI US 3950363 19760413

AI US 1975-556768 19750310 (5)

DT Utility

EXNAM Primary Examiner: Jiles, Henry R.; Assistant Examiner: Dentz, Bernard I.

LREP Spaeth, Earl C.

CLMN Number of Claims: 25

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 2118

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The disclosure includes novel cyclic ethers of the formulas: ##SPC1##

In these formulas, X and Y are --O-- or a valence bond with the proviso that one of X and Y is --O-- and the other is a valence bond; R is hydrogen, alkyl of one to 4 carbon atoms, inclusive, or a pharmacologically acceptable cation; R.sub.2 and R.sub.3 are hydrogen, methyl, or ethyl; and A is ##EQU1## wherein R.sub.4 is hydrogen, methyl, or ethyl with the proviso that R.sub.2 and R.sub.3 are both hydrogen when R.sub.4 is methyl or ethyl. The compounds of the first of these formulas are useful as vasoconstrictors and enhancers of platelet aggregation, and are useful in the control of bleeding in mammals, including man. The compounds of the second of these formulas are useful in the treatment of inflammation.

L5 ANSWER 79 OF 80 USPATFULL

AN 75:52723 USPATFULL

TI Isoindolo [7,1,2-hij]quinolines

IN Levine, Seymour D., North Brunswick, NJ, United States

PA E. R. Squibb & Sons, Inc., Princeton, NJ, United States (U.S. corporation)

PI US 3910926 19751007
 AI US 1973-417157 19731119 (5)
 RLI Division of Ser. No. US 1972-215189, filed on 3 Jan 1972, now patented,
 Pat. No. US 3819624, issued on 25 Jun 1974
 DT Utility
 EXNAM Primary Examiner: Daus, Donald G.; Assistant Examiner: Wheeler, David
 E.
 LREP Levinson, Lawrence S.; Smith, Merle J.; Barrack, Donald J.
 CLMN Number of Claims: 8
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN.CNT 798
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Isoindolo[7,1,2-hij]quinolines are provided having the structure
 ##SPC1##

Wherein R.sup.5 can be hydroxyl, halogen, substituted amino, alkoxy,
 acyloxy, aryloxy, substituted amido, and amino-substituted amido; and
 R.sup.6 is hydrogen; and R.sup.5 and R.sup.6 can be taken together to
 form =O; X, Y, R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are as defined
 below; and which are anti-inflammatory agents, central nervous system
 depressants, inhibitors of cyclic AMP phosphodiesterase and
 sun-screening agents.

L5 ANSWER 80 OF 80 USPATFULL
 AN 74:45598 USPATFULL
 TI PREPARATION OF NOVEL DERIVATIVES OF 2,3
 DIHYDROXYPROPYL-N-(7 OR 8
 CHLORO-4 QUINOLINYL)ANTHRANILATE
 IN Theriault, Robert John, Kenosha, WI, United States
 Karwowski, James Paul, Mundelein, IL, United States
 Wideburg, Norman Earl, Waukegan, IL, United States
 PA Abbott Laboratories, Chicago, IL, United States (U.S. corporation)
 PI US 3839152 19741001
 AI US 1973-359141 19730510 (5)
 RLI Division of Ser. No. US 1971-190690, filed on 19 Oct 1971, now patented,
 Pat. No. US 3790578
 DT Utility
 EXNAM Primary Examiner: Tanenholtz, Alvin E.
 LREP Niblack, Robert L.; Krei, Joyce R.; Mallare, Vincent A.
 CLMN Number of Claims: 1
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN.CNT 171
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB A process of preparing novel derivatives of 2,3-dihydroxypropyl-N-(7 or
 8-chloro-4-quinoliny)anthranilate. The compounds are represented by the
 formula ##SPC1##

Wherein the chloro is in the 7- or 8-position and R is --CH.sub.2
 OCH.sub.3. The compounds are prepared by microbial transformation of
 2,3-dihydroxypropyl-N-(7 or 8-chloro-4-quinoliny)anthranilate. The
 compounds are useful as analgesic and anti-inflammatory agents.

=> log h

COST IN U.S. DOLLARS	ENTRY	SINCE FILE SESSION	TOTAL
FULL ESTIMATED COST		124.75	200.36
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)			
TOTAL			
CA SUBSCRIBER PRICE		0.00	-0.56

SESSION WILL BE HELD FOR 60 MINUTES
 STN INTERNATIONAL SESSION SUSPENDED AT 10:10:50 ON 30 MAR
 2000

L5 ANSWER 17 OF 80 USPATFULL
 AN 1998:156821 USPATFULL
 TI Composition containing peptides and nucleic acids and methods of making same
 IN Kochel, Bonawentura, Wroclaw, Poland
 PA Immune Modulation Maximum, New York, NY, United States (U.S. corporation)
 PI US 5849196 19981215
 AI US 1996-726650 19961007 (8)
 DT Utility
 EXNAM Primary Examiner: Elliott, George C.; Assistant Examiner: Larson, Thomas
 G.
 LREP Carrier, Blackman & Associates, P.C.; Carrier, Joseph P.; Esser, William
 F.
 CLMN Number of Claims: 16
 ECL Exemplary Claim: 9
 DRWN 6 Drawing Figure(s); 3 Drawing Page(s)
 LN.CNT 946
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB An improved composition containing peptides and nucleic acids has active components, i.e., which heighten the phagocytic activity of neutrophils, consisting of molecules with a molecular weight of at least 8 kDa, and preferably at least 15 kDa. The active components comprise peptides without aromatic portions and will absorb light at an absorption band of .DELTA..lambda.=200-235 nm, .lambda..sub.max =205 nm, in the UV spectrum. The composition is nontoxic and is formulated using casein, blood albumin, beef peptone, nucleic acid (RNA) and a base such as sodium hydroxide. The composition stimulates phagocytic activity of neutrophils if used at sufficient concentrations. A separate composition is obtained using the same components of manufacture, but filtering or centrifuging the composition to a molecular weight of <8-15 kDa which inhibits phagocytic activity of neutrophils for application in treating autoimmune diseases.

L3 ANSWER 17 OF 35 PROMT COPYRIGHT 2000 Gale Group

AN 1998:149751 PROMT

TI Advanced Viral Research Corp. Announces Extension of Research Agreement with National Cancer Institute

SO PR Newswire, (24 Mar 1998) pp. 0324NYTU003.

LA English

WC 325

FULL TEXT IS AVAILABLE IN THE ALL FORMAT

AB YONKERS, N.Y., March 24 /PRNewswire/ -- Advanced Viral Research Corp. (OTC Bulletin Board: ADVR) today announced that its Materials Transfer Agreement-Cooperative Research and Development Agreement (MTA-CRADA) with the National Cancer Institute (NCI) for research with ADVR's flagship drug, **Reticulose**, has been extended for one year, beginning March 4, 1998 and ending March 3, 1999.

Reticulose is a non-toxic immunomodulator that has been shown to have a broad spectrum of antiviral therapeutic effects in patients. At the NCI, **Reticulose** is being used to study the basic mechanisms of immune responses. This scientific research is led by Dr. Howard Young, Section Chief in the Laboratory of Experimental Immunology at the NCI, an expert on interferon-gamma. Using kidney tumor model systems, Dr. Young is investigating the anti-tumor activity of **Reticulose**. In addition, Dr. Young and his colleagues will study the effects of **Reticulose** on inflammation associated with **rheumatoid arthritis**.

"The extension of this collaborative agreement between Advanced Viral Research Corp. and one of the premier immunology research laboratories is an important event. We expect these research efforts to provide new insights into the therapeutic potentials, and uses of **Reticulose** while adding to our basic understanding of the workings of the immune system," stated Dr. Shalom Z. Hirschman, President and Chief Executive Officer of Advanced Viral Research Corp.

This news release contains forward-looking statements that involve risks and uncertainties, including risks associated with clinical development, regulatory approvals, including application to the FDA, product commercialization and other risks described from time to time in the SEC reports filed by ADVR. **Reticulose** is not approved by the U.S. Food and Drug Administration or any comparable agencies of any other countries.

National Library of Medicine: IGM Results Screen

 Fetch
for Display Download
to Disk Order
Documents Log off
IGM Next
Records Details
of Search Return to
Search Screen Previous
Records

Citations 1 to 5 of 5 from MEDLINE



TITLE: Peptide nucleic acids stimulate gamma interferon and inhibit the replication of the human immunodeficiency virus.

[Full Citation](#)

AUTHORS: Hirschman SZ, Chen CW

SOURCE: J Investig Med. 1996 Aug;44(6):347-51.

[Related Articles](#)

CIT. IDS: PMID: 8795297 UI: 96387866



TITLE: The efficacy of a peptide-nucleic acid solution (Reticulose) for the treatment of hepatitis A and hepatitis B--a preliminary controlled human clinical trial.

[Full Citation](#)

AUTHORS: Cohen M

SOURCE: J R Soc Health. 1992 Dec;112(6):266-70.

[Related Articles](#)

CIT. IDS: PMID: 1469671 UI: 93108371



TITLE: In vitro antiviral activity of a peptide-nucleic acid solution against the human immunodeficiency virus and influenza A virus.

[Full Citation](#)

AUTHORS: Friedland B

SOURCE: J R Soc Health. 1991 Oct;111(5):170-1.

[Related Articles](#)

CIT. IDS: PMID: 1724467 UI: 92177329



TITLE: Ultrastructural and ultrahistochemical studies on the ventral aorta in larvae of a teleost, Poecilia reticulata.

[Full Citation](#)**AUTHORS:** Leknes IL**SOURCE:** Anat Anz. 1986;161(1):43-51.[Related Articles](#)**CIT. IDS:** PMID: 3010778 UI: 86213134**TITLE:** [Reticular hyperplasia of the skin caused by light. Actino-reticulose, actinic-reticuloid].[Full Citation](#)**AUTHORS:** Kortting GW**SOURCE:** Med Welt. 1971 May 15;20:826-7. German. No abstract available.[Related Articles](#)**CIT. IDS:** PMID: 4252502 UI: 71186953

Fetch for Display

Download to Disk

Order Documents

Log off IGM

Next Records

Details Of Search

Return to Search Screen

Previous Records

National Library of Medicine: IGM Full Record Screen

Order
DocumentsLog off
IGMNext
RecordDetails
of SearchReturn
to ResultsReturn to
Search ScreenPrevious
Record

Related Articles

TITLE: Peptide nucleic acids stimulate gamma interferon and inhibit the replication of the human immunodeficiency virus.

AUTHORS: Hirschman SZ; Chen CW

AUTHOR AFFILIATION: Department of Medicine, Mount Sinai School of Medicine, New York, NY 10029, USA.

SOURCE: J Investig Med 1996 Aug;44(6):347-51

CITATION IDS: PMID: 8795297 UI: 96387866

ABSTRACT: **BACKGROUND:** Peptide nucleic acids (PNAs) are newly appreciated molecules consisting of both amino acids and nucleotides that already have been shown to have interesting properties; for example, they are very stable and have antisense activity. Reticulose, a peptide nucleic acid preparation that had been used for many years to treat human viral infections such as influenza, was investigated for inhibitory effects on the replication of the human immunodeficiency virus (HIV) in cell culture systems. **METHODS:** H9 and peripheral blood mononuclear cells (PBMCs) were treated with reticulose before, during, and after infection with HIV-1 at various multiplicities. Treatment of cells with PNA significantly inhibited replication of HIV-1 as measured by synthesis of viral mRNA and p24 protein, reverse transcriptase activity, and syncytial cell formation. Exposure of cells to PNA under conditions that favor transfection of DNA, such as electroporation, markedly enhanced the

inhibition of HIV replication. RESULTS: In experiments to examine the mechanism of inhibition, it was found that PNA stimulated production of a distinctive cassette of chemokine mRNAs in PBMC cultures. Cytokines stimulated by reticulose included gamma interferon, interleukin-6, interleukin-1, and tissue necrosis factor-alpha. **CONCLUSIONS:** These results offer new tools for the study of immune functions and, moreover, open new approaches to the therapy of HIV infection and AIDS.

MAIN MESH HEADINGS: Antiviral Agents/*pharmacology
HIV-1/*physiology
Interferon Type II/*biosynthesis
Nucleic Acids/*pharmacology
Peptides/*pharmacology

ADDITIONAL MESH HEADINGS: Chemokines/genetics
Human
HIV-1/drug effects
Interferon Type II/genetics
RNA, Messenger/biosynthesis
Support, Non-U.S. Gov't
Tumor Cells, Cultured
Virus Replication/drug effects
1996/08
1996/01 00:00

PUBLICATION TYPES: JOURNAL ARTICLE

CAS REGISTRY NUMBERS: 0 (reticulose)
0 (Antiviral Agents)
0 (Chemokines)
0 (Nucleic Acids)
0 (Peptides)
0 (RNA, Messenger)
82115-62-6 (Interferon Type II)

LANGUAGES: Eng



Order Documents



Log off IGM



Next Record



Details Of Search



Return to Results



Return to Search Screen



Previous Record